https://www.pharmaradar360.com hourly 1 https://www.pharmaradar360.com/news hourly 0.95 https://www.pharmaradar360.com/regulators daily 0.9 https://www.pharmaradar360.com/trials daily 0.85 https://www.pharmaradar360.com/pipeline daily 0.9 https://www.pharmaradar360.com/drug-approvals daily 0.9 https://www.pharmaradar360.com/journals weekly 0.8 https://www.pharmaradar360.com/pharma-companies weekly 0.8 https://www.pharmaradar360.com/specialties weekly 0.8 https://www.pharmaradar360.com/sources weekly 0.8 https://www.pharmaradar360.com/newsrooms weekly 0.8 https://www.pharmaradar360.com/pharma-tools weekly 0.8 https://www.pharmaradar360.com/pharma-communities weekly 0.75 https://www.pharmaradar360.com/pro weekly 0.75 https://www.pharmaradar360.com/tools weekly 0.7 https://www.pharmaradar360.com/about monthly 0.5 https://www.pharmaradar360.com/privacy yearly 0.35 https://www.pharmaradar360.com/support monthly 0.35 https://www.pharmaradar360.com/disclaimer yearly 0.35 https://www.pharmaradar360.com/drug/pembrolizumab daily 0.9 https://www.pharmaradar360.com/drug/semaglutide daily 0.9 https://www.pharmaradar360.com/drug/tirzepatide daily 0.9 https://www.pharmaradar360.com/drug/trastuzumab-deruxtecan daily 0.9 https://www.pharmaradar360.com/drug/osimertinib daily 0.9 https://www.pharmaradar360.com/drug/nivolumab daily 0.9 https://www.pharmaradar360.com/drug/dupilumab daily 0.9 https://www.pharmaradar360.com/drug/risankizumab daily 0.9 https://www.pharmaradar360.com/drug/lecanemab daily 0.9 https://www.pharmaradar360.com/drug/atezolizumab daily 0.9 https://www.pharmaradar360.com/article/fda-recasts-drug-packaging-oversight-with-science-and-risk-based-container-closu-212514b16ec9a406 2026-09-05T14:29:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/oric-stock-holds-steady-as-biotech-eyes-next-trial-and-earnings-0490ce6768597bd1 2026-09-05T14:15:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/vrxa-jumps-as-traders-focus-on-biotech-breakout-setup-ffe5bbb195e962d9 2026-09-05T14:08:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/annovis-bio-stock-reacts-to-webinar-plan-and-steep-discount-to-analyst-targets-60ea8056814b23fb 2026-09-05T14:02:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/european-healthcare-professionals-view-greener-pharmaceutical-manufacturing-favo-86972c80169790db 2026-09-05T12:58:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/synh-stock-reflects-syneos-health-s-move-to-go-private-bd6ccbf69dfad23d 2026-09-05T12:31:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/symbiosis-pharmaceutical-services-appoints-jos-vergeest-as-senior-business-devel-90c6b0f056e0860b 2026-09-05T12:29:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-ms-pill-that-beat-standard-therapy-and-cleared-the-safety-bar-its-rival-coul-59dc69ca9441f4d0 2026-09-05T12:23:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/before-the-first-molecule-making-better-target-and-modality-decisions-44248c637b5c8dfc 2026-09-05T11:59:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/bpom-invites-pharmaceutical-industry-to-bolster-clinical-trials-3a5d10ffdcf5d92b 2026-09-05T11:47:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/personalized-cancer-vaccine-breakthrough-ignites-sequencing-sector-tempus-ai-s-p-d35b5a3721aae31d 2026-09-05T11:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-first-drug-for-alexander-disease-247a4f900fe6e339 2026-09-05T10:47:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/crispr-therapeutics-gains-fda-approval-for-casg-2f0879fdfbacbdd9 2026-09-05T10:40:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/etfs-investing-in-beijing-sl-pharmaceutical-co-ltd-class-a-stocks-bbd678d351a029d1 2026-09-05T10:30:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/nykredit-a-s-purchases-new-position-in-teva-pharmaceutical-industries-ltd-teva-49444cde7f7fa55b 2026-09-05T09:42:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/adverum-biotech-advm-free-cash-flow-2024-92-8m-outflow-down-1-2-48a480bd60f45ef8 2026-09-05T09:09:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/medicines-discovery-catapult-backs-uk-biotech-innovators-b7fd54a7eaf805c9 2026-09-05T09:06:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/two-scientists-made-huge-bets-on-impossible-cancer-treatments-they-re-finally-pa-db7a691a13ee6f25 2026-09-05T09:00:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-nyse-teva-given-average-rating-of-moderate-bu-2b9e2a547e63dda0 2026-09-05T08:33:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/symbol-stock-quote-price-and-forecast-eb86857047c09609 2026-09-05T08:16:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/sls-stock-rises-overnight-healthcare-execs-tout-aml-drug-as-game-changer-ahead-o-12a417a1f58a5f3b 2026-09-05T07:59:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/inhibrx-to-present-inbrx-106-phase-2-data-in-head-and-neck-cancer-study-7bc60e333f0cfecf 2026-09-05T07:31:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-extra-year-that-made-all-the-difference-2d795dc0f906e085 2026-09-05T07:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tarsus-pharmaceuticals-acquires-alkeus-gildeuretinol-for-stargardt-disease-4dd965f22b50d017 2026-09-05T06:41:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/pelacarsen-fails-to-meet-primary-endpoint-in-phase-3-lp-a-trial-0ea1f443261d0062 2026-09-05T06:36:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/this-small-cap-biotech-posted-impressive-brain-cancer-data-but-there-s-a-catch-4e3e96481ca46f3d 2026-09-05T06:32:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/biomarin-pharmaceutical-bmrn-what-is-behind-the-fresh-attention-95db6bebddecf959 2026-09-05T05:39:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/astrazeneca-s-breast-cancer-drug-etcamah-gets-us-fda-approval-41925e83fc4b1cbb 2026-09-05T04:56:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/top-3-japanese-ai-healthcare-stocks-to-watch-in-september-2026-75b00280cb33900d 2026-09-05T04:40:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/hoth-s-pivot-from-biotech-to-space-tech-sparks-massive-rally-in-stock-retail-und-fea1a8d486dec34b 2026-09-05T04:33:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-grand-pharmaceutical-group-sehk-512-is-back-in-the-spotlight-12d7b62e79cc7d2b 2026-09-05T03:53:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/this-biotech-stock-crashed-28-today-after-announcing-second-reverse-share-split-b0b395313df17574 2026-09-05T03:29:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbv-stock-gains-on-winning-fda-approval-for-rare-blood-cancer-drug-1cabfd1aed67f747 2026-09-05T03:09:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-and-the-glp-1-story-behind-its-fair-value-gap-08239ff0c5b30182 2026-09-05T02:13:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-lp-a-drug-fails-to-lower-cardiovascular-risk-in-closely-watched-ph-3-tr-4ff0f635ef6e2a9a 2026-09-05T01:18:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-ultragenyx-pharmaceutical-rare-is-down-40-3-after-angelman-trial-failure-and-ec2e08344eda4d1e 2026-09-05T01:08:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32 2026-09-05T00:54:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-d1c53177db8b563e 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-996c27d729239060 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-92fcf08a2d412711 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-ef9c977453dc80fe 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-fa610d76a59693f0 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-f18275d24e838e9e 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-298de22c7083a9f7 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-6a314617fea45d63 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-24a547145d61b8cc 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-174e5e0a1f668088 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-f25d6992162b7f77 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-36d168f559a4000c 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-90943d18e1dcace7 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/home-page-62b3c221f3f980e0 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-analysis-of-antiviral-therapies-in-chronic-hcv-patients-clinical-out-4bcf8aa6f1254c3f 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comment-on-efficacy-and-safety-of-intraoperative-hyperthermic-intraperitoneal-ch-7f64a205b02b1996 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/alianza-terapeutica-y-cambio-clinico-en-psicoterapia-digital-una-revision-sistem-23f9bbee850cb5bf 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/seroprevalence-of-helicobacter-pylori-among-patients-attending-ignatius-ajuru-un-e817d25f76b3529f 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-profile-and-renal-anomalies-associated-with-culture-positive-urinary-tr-6a058814af559638 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-profile-and-outcomes-of-paediatric-traumatic-brain-injury-an-experience-b5e4628be31d8910 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-profile-and-outcome-of-childhood-cancer-over-2-years-at-a-tertiary-care-0901d6200d429697 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/lt-b-gt-acute-bacterial-meningitis-prevalence-clinical-profile-and-outcome-lt-b-44fb431196e05a86 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluation-of-the-three-component-drug-regimen-glutamyl-tryptophan-bendazole-asc-940b332fe1c13baf 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmacokinetic-parameters-of-a-combination-drug-containing-imidazolyl-ethylamid-0baeae1ef1811af1 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-chinese-medicine-compound-on-intestinal-bifidobacteria-recovery-and-cd-df2c56cc86dd2216 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/features-of-intestinal-lesions-in-the-clinical-course-of-inflammatory-bowel-dise-970e38ee5edd81b4 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/unusual-pulmonary-vein-variations-a-new-case-report-and-its-clinical-significanc-4bf10286dc5f4ada 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/impact-of-proton-pump-inhibitor-therapy-on-micronutrient-and-cognitive-function-62002486099678ba 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/phospholipid-drug-complex-tagged-snedds-lipid-based-approach-for-oral-bioavailab-c7c8e348c293d485 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-magnesium-supplementation-in-hypomagnesemia-on-wound-healing-in-diabet-3235a2566597306d 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/assessment-of-parent-s-knowledge-attitude-and-practice-regarding-self-medication-1a082b786f063c53 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-of-latent-fingerprints-using-air-dried-plant-extract-powders-an-eco-24b27d64d6b9e5da 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/serum-albumin-and-c-reactive-protein-as-predictors-of-intradialytic-hypotension-527e7083789e3728 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/indomethacin-loaded-nano-emulsions-a-promising-topical-platform-for-oral-mucosit-de142850bb89dfba 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effectiveness-of-a-structured-educational-intervention-on-internalized-shame-and-8a264b80d1242c1f 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-characteristics-and-risk-factors-for-trocar-site-hernia-a-single-center-6acba75f63e42b8d 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-effect-of-phase-i-cardiac-rehabilitation-exercise-training-combined-with-res-7e11f5cc1ac0f5aa 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/obstetric-and-non-obstetric-sources-of-maternal-sepsis-and-their-clinical-outcom-89a82e968531c98d 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/membrane-dependent-adsorption-of-lacosamide-in-crrt-implications-for-drug-dosing-11985cfa1e92275b 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/computational-mechanistic-analysis-of-olefin-formation-in-ketyl-radical-mediated-387a0d92a6b60c7c 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/vitamin-d3-attenuates-delirium-like-cognitive-impairment-in-a-postoperative-mous-eb241ee61b13fa6d 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sleep-disorders-and-type-2-diabetes-mellitus-a-narrative-review-of-evolving-rese-730f270c3499e5e1 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-nutrition-counseling-on-undernutrition-among-children-aged-6-23-months-663f1c3275a7ca69 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-the-clinic-a-feasibility-trial-of-the-super-skills-for-life-program-for-c-61c73a836a739fb4 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/breast-cancer-risk-epigenetic-aging-and-dna-methylation-clocks-dc075747faf8999c 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/occurrence-levels-of-alexithymia-in-clinical-nurses-a-systematic-review-and-meta-108c5446f3f8e4c7 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-context-feedback-visibility-cfv-framework-mechanisms-of-ai-empowered-clinica-7efd35f46f69cb99 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/critical-insights-into-metastatic-patterns-of-odontogenic-tumors-clinical-charac-eb9af3d399b9272e 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-consequences-treatment-status-and-parental-awareness-of-traumatic-denta-fc0a1196aaf37063 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/treatment-of-vulvovaginal-atrophy-using-vaginal-dilators-in-addition-to-usual-ca-4242fd54c94d016c 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/high-flow-nasal-cannula-versus-standard-oxygen-therapy-for-adult-acute-hypoxemic-d3e330c8f799849a 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/police-drug-seizures-without-arrest-before-and-during-a-decriminalization-pilot-688876b1023a3c02 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-and-validation-of-a-clinical-prediction-model-for-gastrointestinal-h-1b609f467ec5b699 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/zmynd11-mbtd1-rearranged-acute-myeloid-leukemia-in-chinese-adolescents-and-adult-d8038dd60bc332d8 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-characteristics-and-recovery-after-intravenous-thrombolysis-for-acute-i-1221e2272189e5a2 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-decision-making-and-management-of-gliomas-in-the-second-trimester-case-9fe4c99be97c0c3e 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/routine-clinical-test-markers-with-mri-anatomical-anchoring-for-dysphagia-risk-i-8d698514170983c8 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/blood-transcriptomic-profiling-identifies-hub-genes-with-diagnostic-and-clinical-3c85b97a8b7e0394 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/autonomic-regulation-as-a-mechanistic-pathway-linking-transcutaneous-auricular-v-8b6316e7240ed992 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/changing-clinical-presentation-of-pediatric-celiac-disease-over-time-632b1d895da2aaca 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/technology-meets-time-assessing-the-impact-of-clinical-decision-support-tools-fo-aae966df0229d21c 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/stroke-clinical-documentation-education-program-in-australia-and-new-zealand-c16e50de14a9a450 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/telehealth-in-pediatrics-a-quick-review-4397f75451a924a4 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/best-case-worst-case-a-multisite-randomized-trial-of-scenario-planning-for-patie-97c9bff1883fe3f8 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/financial-impact-of-a-long-acting-injectable-cabotegravir-rilpivirine-program-a-f2e44332314ebf3f 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-scandinavian-perspective-of-the-projected-lifetime-cost-effectiveness-of-rivar-f7f7bd844069977d 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ufasomal-nanocarriers-for-enhanced-cardiac-delivery-of-nifedipine-a-novel-strate-afda9338ec3346e3 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-of-hptlc-method-for-simultaneous-estimation-of-gatifloxacin-and-flur-3592b3a4c663329e 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/when-fear-became-the-barrier-to-care-lessons-of-a-clinical-rapid-response-during-40975bffd5c0cbd9 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/age-associations-sex-differences-and-interrelationships-of-five-skeletal-maturit-2bd54d31e65ec6bc 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gastrointestinal-tolerance-and-compliance-during-a-2-week-intervention-of-reform-a1263f1c370bc29d 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/investigating-the-short-term-reliability-of-health-related-physical-fitness-asse-5eeefa5eca21ad72 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/burden-of-complex-multimorbidity-and-disparities-in-care-and-support-among-older-657be33be128dfb8 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/artificial-intelligence-in-echocardiography-and-point-of-care-ultrasound-applica-d5c8cbce011330d7 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-of-a-recombinant-bacillus-ligniniphilus-l1-laccase-rice-straw-biocha-3b201a8978622e70 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/exploiting-binary-eutectic-fatty-acid-systems-for-thermoresponsive-nanocarriers-7f4d2fdc58ed3b61 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-efficacy-of-betamethasone-ciprofloxacin-and-saline-impregnated-nasal-a9a8c4422417da23 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bulge-progenitor-cells-a-promising-frontier-in-hair-follicle-regeneration-and-cl-3d7c2672d8da15c8 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/antibody-drug-conjugates-in-the-treatment-of-esophageal-cancer-d07dfe0cb30e9961 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effects-of-supervised-exercise-immediately-after-bariatric-surgery-results-from-7145cbcebd22bb81 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cross-tier-implementation-gaps-in-pharmaceutical-waste-management-evidence-from-1b0cb6f2ef757071 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/institutional-phronesis-theorizing-how-us-primary-care-clinicians-navigate-compe-1dfeb77573914e75 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/systemic-evaluation-of-immune-cells-and-cytokines-in-patients-with-different-cli-30b411be4f72f0f0 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/concurrent-emergency-head-and-cervical-spine-ct-utilization-temporal-trends-diag-dc8d9f020852509c 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/moraxella-species-isolated-from-blood-cultures-in-europe-moraxeu-a-multicentre-s-9dbfe48cf40dc4fa 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ibero-american-consensus-on-reactive-arthritis-definition-diagnosis-and-manageme-059966e2abc9b36a 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/chloroquine-and-hydroxychloroquine-retinopathy-in-a-cohort-with-rheumatic-diseas-d7f29972f4ddb543 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-practice-guidelines-for-duodenal-cancer-2025-4164950c8ec243b7 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-effect-of-a-smartphone-based-educational-intervention-on-the-supportive-care-75ad4aa4690acbf1 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comment-on-survival-of-esophageal-squamous-cell-carcinoma-achieving-pathological-ed2136739cfc6e80 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-analysis-of-post-neurosurgical-intracranial-infections-distinct-clin-1129b9da52f1058f 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/video-assisted-versus-conventional-surgical-informed-consent-in-visceral-surgery-5313463edb15ecf5 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/when-88-meets-72-refining-the-clinical-relevance-of-cesarean-scar-disorder-crite-add3ff9d204cc156 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-says-closely-watched-cholesterol-study-failed-to-meet-goal-c974947767e107ee 2026-09-04T23:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/retatutride-how-the-hunger-for-a-new-weight-loss-drug-is-feeding-an-industry-of-a21a403b35712d2a 2026-09-04T23:47:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/retatutride-how-the-hunger-for-a-new-weight-loss-drug-is-feeding-an-industry-of-3263ee450ff58f10 2026-09-04T23:47:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/krystal-biotech-president-r-d-suma-krishnan-sells-8-98m-in-stock-df91173fa47ede2e 2026-09-04T23:46:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/royalty-pharma-announces-update-on-novartis-phase-3-topline-results-for-pelacars-bc1f4aaad1074d58 2026-09-04T23:20:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/krystal-biotech-krys-r-d-head-sells-25-000-shares-under-trading-plan-cb1e83004cab11e9 2026-09-04T23:16:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/krystal-biotech-nasdaq-krys-ceo-sells-25-000-shares-under-trading-plan-769f72394190993e 2026-09-04T23:15:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-limited-teva-discusses-positive-topline-results-f-1d262411b8d372e2 2026-09-04T23:08:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-microstructure-intelligence-matters-in-pharma-canva-4ef5ef0edcc9f338 2026-09-04T22:57:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmtech-weekly-roundup-september-4-2026-7533b9f88b60a135 2026-09-04T22:57:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/budget-for-specialty-pharmaceutical-benefits-set-at-6-73-billion-299e9cedc1dc9a28 2026-09-04T22:25:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/price-to-earnings-forward-of-beijing-science-sun-pharmaceutical-co-ltd-class-a-s-f590ad736661f465 2026-09-04T22:18:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/adrx-ipo-news-sirna-biotech-adarx-pharmaceuticals-files-for-a-100-million-ipo-30c48b5f6850499b 2026-09-04T22:06:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-care-down-on-retreat-from-risky-biotech-area-health-care-roundup-8a5b670f583adb85 2026-09-04T21:26:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-temperature-controlled-shipping-boxes-market-outlook-to-2035-2902f61bf810da37 2026-09-04T21:21:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/louisiana-et-al-v-food-and-drug-administration-a-case-working-its-way-through-fe-66ad1de31182382d 2026-09-04T21:16:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-experimental-cardiovascular-drug-fails-a-pivotal-study-9ae30b6c2563ebf7 2026-09-04T21:13:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-a3f827cc018f20b4 2026-09-04T21:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-rallies-hrt-manufacturers-amid-us-wide-estradiol-patch-shortage-efd1ca9295aa5ff4 2026-09-04T20:37:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/krystal-biotech-nasdaq-krys-holder-to-sell-25-000-founders-shares-7f15233a6b29e374 2026-09-04T20:35:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/krystal-biotech-krys-insider-moves-to-sell-2017-shares-in-a-multimillion-dollar-ca5b3b0ebae69cca 2026-09-04T20:34:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-announces-lp-a-horizon-phase-iii-topline-results-for-pelacarsen-in-pati-867479c87b906007 2026-09-04T20:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/anmat-emitio-una-carta-de-advertencia-a-ugal-farmaceutica-s-a-por-incumplimiento-3ee3a16bbcc2f661 2026-09-04T20:25:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-clears-ind-for-acepodia-s-dual-payload-adc-ace723-562cd23a52fb1859 2026-09-04T19:55:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-virtus-lifesci-biotech-products-etf-bbp-affects-rotational-strategy-timing-ba10d3e23ea6d928 2026-09-04T19:54:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/price-to-sales-forward-of-ch-biotech-r-d-co-ltd-twse-6534-c184512b86e2c429 2026-09-04T19:31:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/vertex-vs-regeneron-which-biotech-giant-is-the-better-buy-right-now-d7df5d6599582fab 2026-09-04T19:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cipla-partners-with-qilu-pharmaceutical-to-commercialize-a-keytruda-biosimilar-i-02acbe0f0bb78c07 2026-09-04T19:27:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/gan-lee-pharmaceuticals-ade7c29f5fb27ce0 2026-09-04T19:22:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-green-light-for-zanvastro-in-alexander-disease-f88683f75405f5fc 2026-09-04T19:04:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/anmat-presento-la-experiencia-argentina-en-vigilancia-y-control-post-comercializ-2488a1f0ffb5901f 2026-09-04T19:04:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/vertex-vs-regeneron-which-biotech-giant-is-the-better-buy-right-now-793b08ac95d107c2 2026-09-04T19:03:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/vertex-vs-regeneron-which-biotech-giant-is-the-better-buy-right-now-f1e282e1506ed3dc 2026-09-04T18:50:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-nyse-teva-price-target-raised-to-48-00-at-ubs-gro-3718e94073907b30 2026-09-04T18:45:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/beone-onc-secured-a-pharmaceutical-tariff-exemption-after-more-than-1b-of-u-s-ma-75b7a23003457f36 2026-09-04T18:44:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/porcine-kidney-xenotransplantation-as-a-bridge-to-allotransplantation-a-first-in-5c486e8a729f25d2 2026-09-04T18:16:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-goldman-sachs-group-issues-pessimistic-forecast-for-ultragenyx-pharmaceutica-679089eff3672c38 2026-09-04T18:15:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/building-for-the-future-of-drug-delivery-with-dare-bioscience-4079e561edcbb5b9 2026-09-04T18:07:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/jos-vergeest-appointed-at-symbiosis-bringing-three-decades-of-pharmaceutical-exp-5f4fcc7a587f046f 2026-09-04T18:06:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/rare-brain-disorder-gets-its-first-fda-drug-approval-c9ccac9f39aac17f 2026-09-04T17:52:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-pharma-will-navigate-the-ndc-12-transition-1f1847cc4d566e17 2026-09-04T17:51:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-pauses-autoimmune-car-t-trials-following-three-deaths-a0de109acce01059 2026-09-04T17:46:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/h-c-wainwright-maintains-legend-biotech-legn-us-with-buy-rating-maintains-target-6ca84d6d182f68e0 2026-09-04T17:42:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/police-response-insufficient-for-crimes-against-pharmacies-report-owners-d78a9e8392e46ad6 2026-09-04T17:38:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/call-to-expand-shingles-vaccine-following-cardiovascular-research-bf9e54f857af915a 2026-09-04T17:38:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-zanvastro-pharmexec-ae001a6459d6b4f4 2026-09-04T17:37:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-strikes-again-closes-canteen-at-thane-government-hospital-after-d572cd8cb0d16e22 2026-09-04T17:33:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/medicines-discovery-catapult-backs-two-u-k-biotech-companies-tackling-chronic-di-2a91e1113b88c4ae 2026-09-04T17:28:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/news-biotech-firm-inks-office-deal-in-south-san-francisco-cb565b9f4316a748 2026-09-04T16:55:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/cockroach-found-in-patient-s-meal-fda-flags-violations-shuts-thane-hospital-cant-ac237dad9aeb2eb7 2026-09-04T16:38:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/novo-nordisk-advances-new-injectable-obesity-drug-in-key-phase-3-trial-55906840ab9c4121 2026-09-04T16:34:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/pfizer-s-tilrekimig-eczema-trial-a-fresh-phase-3-catalyst-for-pfe-investors-e00d8772d820793f 2026-09-04T16:34:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/medtronic-executives-to-speak-at-upcoming-investor-conferences-fe0d7b9078a66a84 2026-09-04T16:34:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/this-biotech-wins-a-big-fda-approval-why-wall-street-is-shrugging-12974b5b8bd07770 2026-09-04T16:13:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/trailing-rivals-abbvie-scores-win-with-dual-acting-myeloma-drug-43b029fb663ef74c 2026-09-04T16:10:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/registration-open-for-sacramento-biotech-summit-at-aggie-square-9524742bf36c6654 2026-09-04T16:05:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/genencell-s-book-value-hits-zero-amid-allegations-kim-seung-won-sought-clinical-5a6dd76f4aaac2ed 2026-09-04T16:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ai-is-revolutionizing-biotech-can-regulation-keep-up-adcb553923ba9ce2 2026-09-04T15:57:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-stocks-to-watch-and-pharma-industry-news-72f24107382921a8 2026-09-04T15:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharma-pulse-mfn-expansion-goodrx-s-family-plan-csafe-s-reusable-cover-bb893e9003f89293 2026-09-04T15:44:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-upgraded-to-investment-grade-by-s-p-global-ra-5a9fbf7fc25733d9 2026-09-04T15:40:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-wall-street-analyst-spotted-the-trial-freeze-then-came-news-of-three-deaths-25accbeac58f1638 2026-09-04T15:33:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/daiichi-unit-american-regent-recalls-3-epinephrine-batches-on-particulate-leakag-9cab5fe17071222c 2026-09-04T15:12:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/va-secures-10b-in-pharmaceutical-price-reductions-so-far-in-fy-2026-e5596cc90a2b64ca 2026-09-04T15:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/russia-attacks-teva-pharmaceutical-company-and-world-health-organization-warehou-01cc1de6ad42dde7 2026-09-04T14:51:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/former-i-mab-chief-joan-shen-s-neushen-banks-80m-for-3-brain-health-drugs-ac240652b9285082 2026-09-04T14:47:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/veraxa-biotech-stock-rises-after-naming-raju-willener-as-cfo-by-investing-com-7a40239d54805b10 2026-09-04T14:43:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-digest-expedited-regulatory-pathways-for-biologics-79b10a02d16847cd 2026-09-04T14:43:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/cipla-announces-exclusive-partnership-with-qilu-pharmaceutical-for-the-licensing-b2c729fc50676a80 2026-09-04T14:24:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-indonesia-to-the-world-support-beta-pharmacon-s-manufacturing-excellence-wi-c162257ad511f15b 2026-09-04T14:22:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-is-back-with-h1-progress-smoothing-glide-path-through-end-of-year-truist-2ed583a9b16ec59c 2026-09-04T14:11:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/weekly-buzz-ions-mist-biib-azn-win-nods-tcrx-nvs-cut-jobs-ovid-vir-data-regn-pas-e786e36eef9e1887 2026-09-04T14:09:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/federal-appeals-court-to-consider-louisiana-s-arguments-for-banning-telehealth-a-176f77491e2393f9 2026-09-04T14:04:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/q-a-mckesson-s-scott-mooney-on-closing-dscsa-data-exchange-gaps-6c5b4921e97cadab 2026-09-04T14:04:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/cover-of-vaccination-evaluated-rapidly-cover-programme-april-2025-to-march-2026-bf86900b8a68bc94 2026-09-04T14:00:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-takes-another-look-at-botanical-drugs-5d3fbf966f8a0faf 2026-09-04T13:51:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/cockroach-found-in-patients-meal-fda-shuts-down-kalwa-hospital-canteen-after-ins-a1552b2176401afc 2026-09-04T13:49:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/top-biotech-deals-in-august-2026-648c8cfdb1b56b15 2026-09-04T13:21:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/barclays-issues-pessimistic-forecast-for-ultragenyx-pharmaceutical-nasdaq-rare-s-941455bfd6b4c414 2026-09-04T13:16:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/israeli-biotech-firm-picks-indiana-for-north-american-headquarters-00dcd5724fbe51b3 2026-09-04T13:04:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/clearmind-medicine-stock-slides-friday-what-s-happening-e87647c65615b7b7 2026-09-04T12:59:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/huntsville-biotech-company-diatherix-laboratories-to-close-55-jobs-affected-14e605b10dab7b04 2026-09-04T12:52:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-potentially-blinding-eye-disease-has-no-fda-approved-therapy-tarsus-bought-a-c-05f52a650d30f2e8 2026-09-04T12:42:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/jeol-launches-benchtop-scanning-electron-microscope-fe29c93ef626d8e3 2026-09-04T12:37:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-year-after-big-pharma-s-pull-back-from-the-uk-what-s-changed-91ea46f4b66d8ec6 2026-09-04T12:36:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-s-etentamig-cuts-risk-of-progression-by-60-in-phase-3-multiple-myeloma-tr-005918f5e5ae6fbb 2026-09-04T12:31:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/thyroid-medication-lot-recalled-nationwide-98aeb5228b273e29 2026-09-04T12:28:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/roche-gets-phase-3-trial-waiver-for-higher-dose-of-multiple-sclerosis-drug-c9bae14d474c5b7a 2026-09-04T12:26:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/251b583e1d4ec3f7 2026-09-04T12:15:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/lifepak-35-monitor-defibrillator-6c5b82584c6ee1da 2026-09-04T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/imagertm-ii-angiographic-catheter-31ad1b2e722a9f05 2026-09-04T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gore-viabahn-endoprosthesis-with-propaten-bioactive-08e5d69ab1e55cb9 2026-09-04T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/eu-court-adviser-backs-challenge-to-pharmaceutical-wastewater-charges-f5177be301b558f1 2026-09-04T11:52:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/vrxa-424b-filings-veraxa-biotech-ag-sec-424b-127f1370dd1cec28 2026-09-04T11:51:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/finance-veteran-behind-chf-30b-portfolios-joins-veraxa-biotech-vrxa-as-cfo-87a630a710fcafa4 2026-09-04T11:46:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/veraxa-biotech-names-raju-willener-as-chief-financial-officer-2ada056d45deccc0 2026-09-04T11:36:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/h-c-wainwright-reiterates-legend-biotech-stock-rating-at-buy-3cf72a995f724227 2026-09-04T11:32:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/dimerix-secures-a-34-million-non-dilutive-facility-to-fund-key-clinical-mileston-11179059e4b6422a 2026-09-04T11:27:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/acepodia-announces-fda-clearance-of-ind-application-for-ace723-a-novel-dual-payl-ae666f0288e1ecfe 2026-09-04T11:27:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-drug-substance-to-drug-product-why-integration-matters-in-modern-pharmaceut-6b10776e1e0e3d1e 2026-09-04T11:24:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/lipofit-extreme-fat-burner-recall-fda-finds-toxic-dnp-and-hidden-drug-f7a329c1cd0a7de3 2026-09-04T11:17:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/govt-launches-bio-nivesh-to-drive-private-capital-into-biotech-startups-5267194874c2709e 2026-09-04T11:15:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-pipac-pilot-validating-api-platform-3f397b3ff13ce3bd 2026-09-04T11:12:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/eli-lilly-pharmaceutical-plant-in-upper-macungie-takes-another-step-forward-95d1e0cf0664292e 2026-09-04T11:10:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-nasdaq-rare-rating-lowered-to-hold-at-royal-bank-of-ca-97ea518a6d4e3d57 2026-09-04T11:09:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-intensifies-food-safety-checks-across-goa-cb100a065a1e2f6c 2026-09-04T11:09:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/huntsville-biotech-company-to-close-laying-off-55-workers-be095482a50e2d74 2026-09-04T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bright-minds-biosciences-stock-slides-4-82-as-biotech-volatility-bites-is-more-d-5d0ded2b47af50c1 2026-09-04T10:38:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/perkinelmer-acquires-simotech-to-expand-pharma-manufacturing-automation-25f366eb27ff01e4 2026-09-04T10:36:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/ubs-raises-teva-pharmaceutical-stock-price-target-on-celiac-progress-2a1cb027796bdb4d 2026-09-04T10:36:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ionis-nets-zanvastro-us-approval-in-first-for-alexander-disease-24d83c4ae6c3e865 2026-09-04T10:34:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/trials-by-design-inside-the-new-good-clinical-practice-guideline-6ced499fbb622cde 2026-09-04T10:31:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-nitrosamine-saga-how-one-impurity-rewrote-global-quality-rules-68994d10af08aad4 2026-09-04T10:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/corporate-report-mhra-nice-real-world-evidence-scientific-dialogue-c822a3e3b6d68c78 2026-09-04T10:18:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/la-aemps-informa-de-un-fallo-en-determinados-respiradores-newport-ht70-plus-y-pi-82e0e3d07eaa76ab 2026-09-04T10:11:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/partnership-to-identify-novel-drug-targets-in-neurological-diseases-f341779c9a2a5b0b 2026-09-04T10:10:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/kylo-11-s-97-lp-a-reduction-from-a-single-dose-rewrites-the-durability-standard-d4a5341776eda0a2 2026-09-04T10:07:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/your-questions-answered-the-biggest-pharma-and-biotech-stories-this-week-2a623b8652ef2c75 2026-09-04T10:07:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/superluminal-raises-60-million-to-take-obesity-drug-into-clinic-c7b6cd6243bba671 2026-09-04T09:50:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/decision-human-and-veterinary-medicines-register-of-licensed-manufacturing-sites-de9ea64f4d4c5e91 2026-09-04T09:38:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/notice-register-of-brokers-authorised-to-deal-in-human-medicines-591cf296afe9cc7a 2026-09-04T09:38:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/decision-medicines-new-manufacturing-and-wholesale-dealer-licences-f73993bdb326b18f 2026-09-04T09:38:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/notice-medicines-terminated-and-cancelled-manufacturing-and-wholesale-dealer-lic-85a664947262b9cb 2026-09-04T09:38:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/decision-human-medicines-register-of-licensed-wholesale-distribution-sites-6901963b073e5f1a 2026-09-04T09:38:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/cee-startup-tech-weekly-new-capital-flows-into-ai-biotech-medtech-and-more-d5cb89512c95cd85 2026-09-04T09:33:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/nsf-launches-three-new-science-and-technology-centres-2965520de44b468f 2026-09-04T09:23:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-stocks-at-52-week-highs-atto-halo-ikt-tvtx-atrc-38a6ce892e6ee1f3 2026-09-04T09:15:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/rakovina-therapeutics-shifts-72-of-budget-to-ai-cancer-programs-4fe1118ec6da23ab 2026-09-04T09:11:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/myamici-and-my-green-lab-collaborate-to-improve-sustainable-lab-purchasing-4d8e208884ea3e93 2026-09-04T09:05:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/takeda-pharmaceutical-tse-4502-wins-mimrylo-approval-is-the-stock-still-trading-faa2c56c2669f565 2026-09-04T09:02:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-sensors-behind-pharmaceutical-monitoring-6be7cd5b8bc3f6cc 2026-09-04T08:53:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-discovery-alone-does-not-change-a-life-biotech-executive-says-eabe16cd0617d45a 2026-09-04T08:52:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/wellington-management-group-llp-reduces-stock-position-in-ultragenyx-pharmaceuti-8c69afe9c0111bad 2026-09-04T08:45:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-first-ever-drug-for-alexander-disease-e097dbb9bd0de18e 2026-09-04T08:44:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/russia-has-attacked-a-teva-pharmaceutical-company-warehouse-in-ukraine-twice-da4d0af29b8c3bc4 2026-09-04T08:34:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/measles-epidemiology-2023-to-2026-1387e9c40489bd37 2026-09-04T08:30:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/melbourne-biotech-immunobiota-progresses-5m-seed-raise-for-world-first-oral-type-b4d5cb9476bd3fbd 2026-09-04T08:27:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/medytox-expands-damages-claim-against-daewoong-pharmaceutical-tenfold-to-500-bil-2f736c6111e11e23 2026-09-04T08:25:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/boletin-sobre-seguridad-de-medicamentos-de-uso-humano-julio-de-2026-c127410c2324efee 2026-09-04T08:19:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/jw-pharmaceutical-launches-chewable-eye-nutrition-candy-eye-crunch-60f809e8ab7fce04 2026-09-04T08:06:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-ukraine-warehouse-hit-twice-in-russian-attack-raising-supply-concerns-f938679799fa6ad7 2026-09-04T07:47:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/argo-s-bw-20805-achieves-96-attack-rate-reduction-in-hae-phase-ii-342c8364b7f69850 2026-09-04T06:40:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/ivonescimab-beats-pembrolizumab-on-overall-survival-in-phase-3-nsclc-trial-26a34a5b8cbfe31c 2026-09-04T06:35:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/hanchorbio-submits-ind-to-u-s-fda-for-hcb303-its-second-tri-specific-immunothera-5b8896c62efe16f0 2026-09-04T06:26:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-advisory-no-2026-1020-public-health-warning-against-the-purchase-and-use-of-a6df66299070d3dc 2026-09-04T06:03:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/accelerated-amortized-payment-of-convertible-bond-installment-e9e80f19df8ee3e8 2026-09-04T06:02:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-advisory-no-2026-1019-public-health-warning-against-the-purchase-and-use-of-d48cd80405cdd564 2026-09-04T05:58:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/sanofi-stock-holds-steady-as-pipeline-data-keeps-focus-on-long-term-239bfcdc011eb9f0 2026-09-04T05:49:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/number-of-shareholders-of-aurisco-pharmaceutical-co-ltd-class-a-sse-605116-06b066c3fb923415 2026-09-04T05:45:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/hanmi-s-once-weekly-hyperinsulinism-drug-advances-in-global-phase-2-321cbe0887abe385 2026-09-04T05:26:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/kangmei-pharmaceutical-banks-on-centralized-procurement-for-expansion-upgrading-694812ab8349f82c 2026-09-04T05:07:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/capital-raising-in-healthtech-singular-photonics-aisel-health-and-trinity-biotec-05ca86013071b2fa 2026-09-04T05:05:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/drugs-and-biologics-5th-cir-fifth-circuit-upholds-fda-s-removal-of-tirzepatide-f-3cd04fea308b8823 2026-09-04T05:01:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/gsk-bets-nearly-1-3-billion-on-hutchmed-s-attc-platform-as-chinese-innovative-dr-2dedf8f6544a45ac 2026-09-04T04:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hanmi-pharmaceutical-completes-phase-2-dosing-of-rare-disease-drug-ea619ac6bd578fa6 2026-09-04T04:50:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/suven-life-sciences-completes-phase-3-enrollment-for-masupirdine-in-alzheimer-s-2900b13463d2bb5e 2026-09-04T04:47:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/party-drug-mdma-approved-by-new-zealand-to-treat-trauma-8d151b223f52b56b 2026-09-04T04:36:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/gc-biopharma-pushes-into-senior-flu-vaccine-market-with-phase-2-3-trial-1d81c1eda1185c5c 2026-09-04T04:26:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-named-official-pharmaceutical-sponsor-of-pga-tour-and-2026-presidents-cup-38bec09ca54775a9 2026-09-04T04:07:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmexcil-to-host-trade-expo-next-week-eyes-1-4-bn-export-opportunities-63091a9298bc8d25 2026-09-04T04:05:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/women-in-clinical-trials-history-and-impact-4e9a42d030d09131 2026-09-04T04:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/40kg-expired-chilli-mixed-meat-and-veg-bengaluru-s-chairman-s-club-kitchen-shut-2e3c3c4c0c15fb56 2026-09-04T03:40:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sen-warren-demands-answers-from-rfk-jr-over-calamitous-response-to-cyclosporiasi-597f451e02e55a45 2026-09-04T03:10:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-on-alert-maharashtra-food-safety-body-rolls-out-hit-list-for-upcoming-festiv-ee15b7cb545e9138 2026-09-04T03:00:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/dimerix-secures-a-34-million-non-dilutive-facility-to-fund-key-clinical-mileston-6092f19054abd1ee 2026-09-04T03:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/genscript-biotech-proposes-spin-off-separate-listing-of-probio-unit-5d18af77e433e3d1 2026-09-04T02:53:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/hutchmed-signs-licensing-deal-with-gsk-for-experimental-solid-tumour-drug-89fa778161cb6ca2 2026-09-04T02:47:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-first-ras-targeting-drug-for-pancreatic-cancer-4302da7134eee7fd 2026-09-04T02:25:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/sino-biopharmaceutical-s-gpc3-adc-drug-wins-fda-clinical-trial-approval-shares-s-dd1df1155335a767 2026-09-04T01:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-rare-reports-61-cornstarch-reduction-in-96-week-phase-a8232257af147e0f 2026-09-04T01:38:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-president-trump-posts-on-truth-social-a-request-from-senator-grassley-for-tru-483ddba2b495b9a6 2026-09-04T01:27:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/dimerix-secures-non-dilutive-funding-for-key-kidney-disease-programs-9f824b90f99b62c1 2026-09-04T00:29:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cipla-licenses-china-s-qilu-pharmaceutical-keytruda-biosimilar-us-rights-ed32477bbc498067 2026-09-04T00:02:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/gc-biopharma-wins-korea-approval-to-run-phase-2-3-trials-of-high-strength-flu-sh-aade03aacbdc6c08 2026-09-04T00:01:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-filed-form-6-k-7fe35a5b8dd5ee97 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/reducing-bureaucracy-and-burden-for-the-repatriation-of-mentally-ill-nationals-b7a59fc750d4cf35 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/advancing-development-of-botanical-drug-products-request-for-information-54023367d77f8ebc 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/performance-review-board-members-3d2655a4c40f3ce0 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-submission-to-omb-for-review-and-approv-26d2dab5b5978447 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tips-for-coping-with-end-of-summer-blues-35de06e0b57dfafe 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/relationship-between-factors-of-mental-and-physical-health-in-medical-students-5f4b30f8c5cebbd6 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/personme-a-clinical-trial-for-personalised-psychiatry-from-your-sofa-fdb0d02e2653888e 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/randomized-clinical-trial-of-a-novel-food-insecurity-intervention-for-patients-w-5dafe13c8fbb030e 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/switching-from-amisulpride-to-cariprazine-real-world-outcomes-in-patients-with-p-6f6571b1e0beb808 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/an-open-label-trial-to-compare-exposures-of-subcutaneous-long-acting-injectable-8c3b310a36dec4f3 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agreement-and-divergence-between-clinician-rated-and-self-report-measures-of-dep-70097379c2737666 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/industry-updates-from-the-field-of-stem-cell-research-and-regenerative-medicine-6b48f3f63dfb8db3 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-landscape-analysis-of-japanese-tolerability-assessments-in-oncology-drug-devel-c3535d8f78f44868 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/safety-and-pharmacokinetics-of-cl-197-a-potent-compound-with-low-cytotoxicity-ag-ced65a36a1609c65 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-review-of-seamless-phase-i-ii-trial-designs-towards-oncology-dose-optimization-fc2481260a3cef12 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/antimicrobial-susceptibility-patterns-among-urinary-bacterial-isolates-a-descrip-ef8277884994cecd 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-immunological-characteristics-of-atopic-dermatitis-severity-in-chil-aa888a38d7392ed8 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/computed-tomography-portal-venous-reconstruction-assisted-endoscopic-ultrasound-764a4336448750ea 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-in-vitro-evaluation-of-systemic-fungicides-and-bioagents-against-pig-eb3ba59e33cd559f 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/lt-b-gt-prevalence-clinical-profile-and-risk-factors-of-peripheral-arterial-dise-b265cf5191c80bd0 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-complexities-in-vulnerable-populations-a-comprehensive-review-of-hemoph-9aed9920ff9c7dc3 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-clinical-spectrum-of-adult-patients-with-hypercalcaemia-attending-a-tertiary-26b79d9d01868107 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/changing-clinical-characteristics-diagnostic-patterns-and-outcomes-of-tuberculos-8c36d12855f22fad 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-outcomes-of-radiation-therapy-as-an-alternative-to-radical-surgery-for-4136b3aadd36e529 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cyp2d6-genetic-variation-and-clinical-response-to-donepezil-and-galantamine-in-a-dae04cbba6871929 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/inflammatory-bowel-disease-in-kazakhstan-phenotypes-disease-activity-and-treatme-be2cf4c817d987d4 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/real-world-treatment-patterns-and-clinical-outcomes-after-first-line-therapy-in-dd7ac1900ddf7276 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effects-of-21-day-vitamin-d-supplementation-on-sports-performance-and-exercise-i-f6005a17065d504f 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/autogluon-based-interpretable-machine-learning-for-clinical-risk-stratification-81eb8b46cadb4655 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/anastomotic-leak-after-esophagectomy-for-cancer-in-enhanced-recovery-protocol-ve-f978ea451f1a066e 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/an-open-label-randomised-controlled-trial-protocol-evaluating-a-siddha-add-on-re-70da0d96993a362f 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/short-term-postoperative-neurocognitive-safety-and-recovery-profiles-of-remimazo-7581cfb050d0396e 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/synergistic-effect-of-insulin-resistance-and-glycemic-variability-on-mortality-i-14988ea6116385ab 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/spatial-niches-of-the-colorectal-cancer-microbiome-differences-interrelationship-9d0da07599e2a98e 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/spontaneous-coronary-artery-dissection-in-sweden-epidemiology-diagnostics-and-cl-7d279917dfad0941 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/current-review-of-pediatric-fas-associated-death-domain-protein-deficiency-expan-5974ea24c31e9923 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-feasibility-and-image-quality-assessment-of-deep-learning-based-virtual-431565aded3c343a 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-coated-balloons-from-evidence-to-practice-and-a-proposed-antithrombotic-the-8903d6bd69ee8461 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-role-of-platelet-activation-factor-cd62p-in-the-occurrence-and-development-o-e515fa7fbf10ddd9 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-of-a-narrative-nursing-competency-training-programme-for-clinical-nu-ac73f915907ab6ef 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-effect-of-implementing-clinical-alarm-nursing-intervention-program-on-nurses-301ce50e71bf78e4 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrated-bioinformatics-and-clinical-validation-identify-hbegf-and-th17-marker-9714f384b8270556 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/multidisciplinary-management-of-concurrent-hypogonadism-diabetes-and-hypothyroid-59828fb4ff13e1a9 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-manifestations-and-local-inflammatory-destructive-changes-in-congenital-f286a1d265ae2332 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pfb-03-study-protocol-diagnostic-performance-and-clinical-application-of-sup-18-18cf216d19eb1db4 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/subscription-drug-pricing-the-evidence-behind-it-comes-from-two-states-and-they-fb5a681525a81b14 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/interlocking-plate-compared-with-conventional-pin-fixation-for-undisplaced-femor-e462acf3cd6625d2 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/study-protocol-for-a-participant-and-evaluator-blinded-randomized-controlled-tri-f5fe7a8850145780 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/total-synthesis-assisted-structure-determination-and-biological-evaluation-of-cy-2e03ad678fc32f11 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/body-mass-index-related-trends-in-adverse-events-with-enfortumab-vedotin-analysi-62f4459ae59076af 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/for-health-study-protocol-for-a-randomized-controlled-feasibility-trial-of-struc-5728f033bb59ce01 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hssynergy-scale-aware-hierarchical-attention-for-interpretable-drug-synergy-pred-738b1b5275bf9512 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/perceived-psychological-stress-is-associated-with-blood-dna-methylation-differen-26546360e66e8507 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-characteristics-surgical-pathways-and-outcomes-of-upper-tract-urothelia-0b2cc0f4b7c3d9c8 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ldl-hypercholesterolemia-in-children-genetic-influence-and-response-to-lifestyle-ce7b949c405458cd 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/preparing-collaborative-practice-ready-graduates-an-exploration-of-practice-tuto-6e187bf07b2565c7 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/loupes-assisted-versus-conventional-orthodontic-bracket-bonding-a-split-mouth-ra-5d8b95a0486774fd 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-between-post-exercise-heart-rate-recovery-and-one-year-clinical-dete-09fc48a8c882f1b3 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/an-evaluation-of-a-community-based-football-for-life-ffl-programme-for-men-proto-a9a3a96d06821792 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/temporoparietal-structural-functional-coupling-abnormalities-in-drug-naive-youth-59e2b1188e53a57b 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-characteristics-and-adrenaline-use-in-anaphylaxis-in-children-a-cross-s-e0e9ca843f9d2436 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-significance-of-prenatally-diagnosed-clenched-hand-genetic-associations-f0f844e3be0e1ffe 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/timing-of-planned-birth-in-women-with-gestational-hypertension-or-pre-eclampsia-220e86b5f0bbdf5a 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/detection-of-carbapenem-resistance-mechanisms-in-difficult-to-treat-pseudomonas-20d24fbf1ce70185 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/photo-quiz-a-bloody-inoculum-yields-a-near-miss-b4a438157e8f33b1 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-implications-of-misfit-in-multiunit-implant-supported-fixed-dental-pros-3c6c672735c91015 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/correction-to-h-scp-prf-scp-bone-block-versus-sausage-technique-for-horizontal-r-1ec51d8a720e1352 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fluoride-as-a-modifier-of-metallome-homeostasis-a-systematic-review-of-animal-st-f9ed92d12befcf72 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/posttherapy-18f-fdopa-pet-findings-in-an-anaplastic-pleomorphic-xanthoastrocytom-6d7cc6b10e65372f 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/blood-pool-and-late-phase-3d-ring-czt-spect-ct-in-painful-os-peroneum-syndrome-ae1c648046114fa6 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-outcomes-of-terlipressin-using-continuous-infusion-versus-bolus-in-pati-5482d83eee4908af 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/promoting-physical-activity-in-the-context-of-clinical-care-for-people-with-hiv-5b2157f3821a2c90 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/treatment-of-shivering-during-intrapartum-cesarean-delivery-under-epidural-anest-57c6111067d38866 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/minimized-atrial-pacing-and-atrial-fibrillation-burden-in-the-danpace-ii-trial-350c940007143658 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/honey-as-a-functional-food-and-nutraceutical-bioactive-properties-health-benefit-be51a8625211aa44 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/acceptability-of-alcohol-based-hand-rub-during-neonatal-care-in-rural-ugandan-ho-a82fee9c9418b54d 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluation-of-clinical-prognostic-factors-for-radium-223-therapy-in-castration-r-deaee7bbce6c39ee 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/multikilogram-scale-process-development-for-a-key-intermediate-of-a-clinical-sta-374c9d9ee5c11a24 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/synthesis-and-self-assembly-studies-of-reusable-cholesterol-based-amphiphiles-in-c887f247fda7d9e3 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/dual-diagnosis-and-drug-related-deaths-2019-2021-an-irish-perspective-b2ae75e4f24f2627 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/risk-factors-and-ergonomic-determinants-of-low-back-pain-in-healthcare-workers-i-d3d19d8f0f0cfce8 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/correction-to-continuous-lumbar-sympathetic-blockade-enhances-the-effect-of-lumb-9ffefe0de2782043 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-outcomes-and-care-in-patients-with-posterior-glenohumeral-instability-t-75d4b1e172212738 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-outcomes-before-and-after-the-introduction-of-clazosentan-in-aneurysmal-cf2997965ba2a2ba 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/z-classification-an-anatomy-based-ridge-sinus-zygoma-classification-and-decision-4ea2c02323803c12 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-a-sodium-fluoride-rinse-on-the-composition-of-early-oral-biofilms-form-5dee5f9feae5edf2 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/safety-and-clinical-outcomes-of-antithrombotic-therapy-in-children-and-young-adu-e73390694d25463c 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/adoption-patterns-of-anti-vascular-endothelial-growth-factor-therapies-in-retina-c75d4754e8531711 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluating-the-causal-effects-of-circulating-metabolites-on-major-depression-dis-9606621b21f1facf 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/2d-4d-digit-ratio-and-brain-volumes-in-alcohol-use-disorder-935fa228c7fd1d90 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sex-specific-differences-in-the-relationship-between-prolactin-and-glucose-metab-e4dfcecb8de4a777 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cvs-call-for-2026-clinical-research-grants-9d5bd7bfcd23e3aa 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/connected-to-others-and-kind-to-self-social-connection-and-self-affiliation-chan-b79d4c9e0419d091 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparing-outcomes-using-low-dose-apixaban-and-anti-xa-monitoring-and-vitamin-k-e54ceb5fe8a7edb2 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-derived-tetrahydropyrazines-for-late-stage-i-i-and-i-i-functionalization-of-076dd7bf0676aa81 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-characteristics-and-concordance-of-anti-scp-mda5-scp-antibodies-a-multi-8d86068927625843 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07805746-peri-graft-cytokine-profile-influence-of-hematologic-disease-and-don-8e6c8907448967ba 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07805655-radiofrequency-treatment-versus-topical-therapy-for-facial-acne-vulg-e105ca43bc1cdb56 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07805616-prognostic-value-of-2026-aha-acc-clinical-categorization-in-acute-pu-b6099e1cf856e5b2 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07805603-hermes-quality-and-safety-of-advanced-respiratory-support-during-pat-cf0e28e1dcd56bb5 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07805330-effects-of-blood-flow-restriction-rehabilitation-on-functional-mobil-15399895d05c5cab 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07804914-integrated-digital-health-approach-to-reduce-hazardous-alcohol-use-a-51be9f13bae0a477 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07804862-efficacy-and-safety-of-rfa-vs-mwa-for-treatment-of-large-benign-thyr-21fa1bc12fb3885f 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07804810-phase-2-clinical-study-of-mwn105-injection-in-participants-with-over-c6373971ef87bc25 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07804537-assessment-of-lung-function-lufu-at-sea-level-la-vs-high-altitude-ha-5d7862dbf016a494 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07804524-assessment-of-total-pulmonary-resistance-spap-co-between-high-altitu-4ea76c8415117dac 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07804485-assessment-of-total-pulmonary-resistance-spap-co-between-high-altitu-8ca88f6869229b5e 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07797790-real-world-patient-experiences-with-inbrija-47c7d0df8d8c143b 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07792954-a-study-to-learn-about-the-study-medicine-called-pf-08653944-taken-o-995bda1142254fa9 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07789678-epidemiological-profile-of-patients-with-idh-mutant-diffuse-gliomas-fc1a760de5691bc7 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07777419-impact-of-subthalamic-nucleus-deep-brain-stimulation-on-cognitive-an-f7491f55bffa8412 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07765888-a-study-to-learn-about-the-study-medicine-called-tilrekimig-in-peopl-67fdcd4960c94571 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07756749-minimal-access-hernia-inguinalis-treatment-of-hernia-25d81963a6899392 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07752472-pstc100-study-in-healthy-adult-subjects-93d2c9efc11a0442 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07703475-a-safety-reactogenicity-and-immunogenicity-trial-of-rvx-scpd9-booste-4dbb03ab6e6cbdd6 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07661641-a-study-of-177lu-lu-a9-0631-and-225ac-ac-a9-0642-with-68ga-ga-a9-621-c010ff9b372bbe62 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07619547-longitudinal-immunophenotyping-of-patients-with-inflammatory-bowel-d-3a796411228812d2 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07600892-pain-at-work-toolkit-definitive-trial-a9ef44442c55c3ae 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07599176-partial-stem-cell-transplant-for-sickle-cell-disease-from-matched-do-d6f5336760d056f1 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07540221-a-study-to-evaluate-the-pharmacokinetics-and-safety-of-xembify-versu-aa54aca5db95b0ce 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07468851-a-study-of-hs-10566-in-patients-with-high-risk-non-muscle-invasive-b-592b8bcc594b8559 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07468071-rollover-study-for-participants-who-have-been-treated-with-and-are-c-26f9d5b014f2d866 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07416604-a-clinical-study-to-evaluate-the-effects-of-nxt007-compared-to-emici-8beab6e252106554 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07416552-a-study-to-investigate-cea-prit-2-0-in-participants-with-metastatic-55abc7deadd2d40d 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07412002-quality-of-end-of-life-care-for-children-with-cancer-033ccf1fcd016dc6 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07361562-a-study-of-a-selective-erbb2-inhibitor-cgt4255-in-patients-with-adva-65c0b155cfb2d2fa 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07314957-impact-of-lifestyle-on-health-maintenance-a-randomized-controlled-tr-b60ef72eb6fe40b6 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07252297-the-role-of-universal-cancer-only-marker-six6-in-diagnosing-non-musc-c4220661217a96fc 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07144111-a-study-to-evaluate-the-effect-of-moderate-or-severe-hepatic-impairm-d7a8b07ae4c940d0 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07111065-fast-for-dm-fatty-acid-supplementation-trial-fast-for-dermatomyositi-ed2b3f59cab40468 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07109336-development-and-prospective-validation-of-a-heterogeneous-treatment-89264028dbc57c55 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07066813-staging-strategies-and-their-association-with-prognosis-and-therapy-d99dee7194218280 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06968988-zanzalintinib-in-combination-with-ipilimumab-and-nivolumab-in-patien-db6e4ff8a5672fd2 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06948097-syk-inhibition-in-mitigating-lung-allograft-rejection-similar-a-tria-28f73f1ac769add4 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06717334-a-study-of-lung-cancer-screening-in-people-with-unexplained-weight-l-71cf788a91583da7 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06526338-adjuvant-ip-001-treatment-for-hcc-patients-following-surgical-resect-122f7299b94f09ee 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06414408-randomized-directly-observed-therapy-study-to-interpret-clinical-tri-9e0888b508a02045 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06364410-testing-the-combination-of-the-anticancer-drugs-trastuzumab-deruxtec-fcf362fefb5cbc8e 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06333392-total-underwater-colonoscopy-tuc-for-improved-colorectal-cancer-scre-e57f0772e54619a5 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06295679-a-study-assessing-repatha-in-combination-with-standard-of-care-soc-c-37b11ef44b4b87e9 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06274749-effects-of-urolithin-a-supplementation-on-glucose-metabolism-in-heal-597167a31fc2a3ba 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06126224-a-study-to-assess-efficacy-and-safety-of-karxt-for-the-treatment-of-6e3f8c503509bdb3 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06112613-mobile-health-for-adherence-in-breast-cancer-patients-9e2b96ceecc25d96 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06062498-elacestrant-vs-elacestrant-plus-a-cdk4-6-inhibitor-in-patients-with-d538ed33b253c89e 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05990946-smartphone-based-remote-symptom-monitoring-to-improve-postoperative-4db774193fdb5643 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05933174-promoting-alternatives-to-sulfonylureas-to-improve-patient-safety-in-dae6234964bbe536 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05906004-post-market-clinical-follow-up-pmcf-study-of-the-pitch-patch-for-the-9b709a78e737ed2a 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05761782-engaging-diverse-and-underserved-communities-in-cancer-awareness-tra-d28f5da13afba930 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05739383-a-study-of-inclisiran-to-prevent-cardiovascular-events-in-high-risk-4e6a86c0c9fb0fdd 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05688605-a-study-of-mrg003-in-the-treatment-of-patients-with-egfr-positive-ad-850b0a572d3e373c 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05198830-testing-the-addition-of-an-anti-cancer-drug-trc102-to-the-usual-chem-2e7a02e16da5d13c 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04815356-phase-i-study-of-anti-cd22-chimeric-receptor-t-cells-in-patients-wit-513fac2cb6d24319 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04230356-trial-of-scheduled-versus-treatment-administration-of-donor-derived-ae1b23464ac5486e 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct02559778-pediatric-precision-laboratory-advanced-neuroblastoma-therapy-d3ed604345b907c1 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01972919-mr-guided-phase-ii-radiotherapy-dose-escalation-in-unresectable-non-27a21a138424243b 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct00001778-evaluation-of-patients-with-ham-tsp-0cdbd31a77066891 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gc-green-cross-receives-ind-approval-for-phase-2-3-clinical-trial-of-high-immuno-cd1bad30dd4bcc4f 2026-09-03T23:55:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-company-diatherix-plans-layoffs-d02964975bdb10a1 2026-09-03T23:32:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/up-to-20-of-children-with-dravet-syndrome-die-before-adulthood-a-long-term-study-947996a6f30c5d47 2026-09-03T23:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/big-executive-summit-lasting-impacts-on-biotech-adoption-6c3380fbbf5485a3 2026-09-03T23:21:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/heartland-bioworks-tackles-indiana-s-biotech-labor-shortage-0bd50c7c15ea84ef 2026-09-03T22:57:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/south-korean-biotech-licensing-deals-top-21-trillion-but-stock-prices-lag-recove-c19271ffd829b2fc 2026-09-03T22:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-first-drug-to-treat-alexander-disease-2347a8d3e2094a59 2026-09-03T22:45:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/polyrizon-raises-4m-as-intranasal-hydrogel-biotech-taps-single-investor-263d61e403693cc9 2026-09-03T22:32:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/viral-infections-biotech-ena-respiratory-inhales-3-million-from-government-fund-f0f84c97aaa50e53 2026-09-03T22:32:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/biontech-vs-moderna-which-is-the-better-cancer-vaccine-stock-to-buy-now-f305da9e4bf862e7 2026-09-03T22:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/exclusive-ai-genomics-could-fuel-biotech-etf-re-rating-as-health-care-trades-at-e233c242c5fc5bf7 2026-09-03T22:17:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/glp-1-drugs-tied-to-higher-male-pattern-hair-loss-risk-06ff0c54eff147c5 2026-09-03T22:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nuvectis-pharma-draws-top-biotech-funds-after-115m-raise-d3d7564b36eab305 2026-09-03T21:56:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/yuce-biotech-raises-7-4m-series-b-for-single-molecule-immunodiagnostics-f5fb8efe43098828 2026-09-03T21:34:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/frost-sullivan-released-the-2026-blue-book-on-the-development-of-hong-kong-stock-41de2d3846971aee 2026-09-03T21:30:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-nasdaq-rare-price-target-cut-to-28-00-by-analysts-at-j-ca3688ee8f6e9d4f 2026-09-03T21:20:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-zilganersen-injection-first-drug-for-alexander-disease-6b9acc160b21d317 2026-09-03T21:15:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/eascra-biotech-expands-worcester-presence-following-8m-nasa-award-6fc2911f07faac6d 2026-09-03T20:50:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/ionis-wins-fda-approval-for-first-drug-for-alexander-disease-a-rare-and-deadly-n-a7c1e1e466156811 2026-09-03T20:47:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-abortion-pill-challenge-delayed-until-after-midterms-e15d10d5d453a121 2026-09-03T20:46:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/latigo-biotherapeutics-reports-second-quarter-2026-financial-results-and-recent-f0c7958de799160f 2026-09-03T20:24:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/former-pfizer-vaccine-chief-joins-vaxcyte-trial-data-is-expected-by-october-s-en-e60f9ae456851bed 2026-09-03T20:12:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/vivani-medical-announces-participation-in-upcoming-investor-conferences-dbc3fad4d44de039 2026-09-03T20:08:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-government-moves-to-counter-ex-us-r-d-2eae451673f1d19f 2026-09-03T20:02:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/federal-judge-delays-mifepristone-lawsuit-until-after-midterms-1f38e6ac46520a46 2026-09-03T19:15:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/b-braun-medical-inc-issues-voluntary-nationwide-recall-of-0-9-sodium-chloride-in-415834284e5488f7 2026-09-03T19:08:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/first-patient-dosed-in-ocu410-phase-3-trial-for-geographic-atrophy-20091e2babf89205 2026-09-03T19:07:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-s-apazunersen-fails-phase-iii-trial-pharmexec-efb96fb396d0db45 2026-09-03T19:02:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/pancreatic-cancer-new-fda-approved-drug-doubles-survival-rates-286037f1b916bd32 2026-09-03T18:55:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/application-of-predictive-modeling-in-the-development-of-amorphous-solid-dispers-4a483a3fd54f6a71 2026-09-03T18:32:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/summit-s-ivonescimab-beats-merck-s-keytruda-on-survival-in-chinese-lung-cancer-t-84a274417ccf13a9 2026-09-03T18:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/10x-genomics-wins-latest-round-in-parse-patent-dispute-ca688952e924af96 2026-09-03T18:00:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/psilocybin-proves-promising-in-neuropathic-pain-mouse-study-4a4e30b11d852ce9 2026-09-03T18:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pancreatic-cancer-drug-shows-early-promise-for-lung-cancer-patients-1f38bf591b8c16d5 2026-09-03T17:36:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-target-of-unusually-large-options-trading-nasdaq-rare-fd456c7a91727ca6 2026-09-03T17:23:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-a-national-licensure-standard-would-change-wholesaler-operations-501f16e6ab0d98b1 2026-09-03T17:19:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-long-shadow-of-early-sugar-consumption-plus-a-reality-check-on-fda-approval-84a9ddf4484e3d92 2026-09-03T17:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/himalayas-1-bayer-and-oric-double-down-on-prostate-cancer-with-new-phase-3-combo-ba25736961e49283 2026-09-03T16:55:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/house-biotech-caucus-is-weighing-ip-security-and-ai-enabled-biotech-policy-f4c2c41e3be75b77 2026-09-03T16:42:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/russian-forces-launch-two-attacks-on-teva-ukraine-pharmaceutical-company-warehou-c2bca94b140e013a 2026-09-03T16:33:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cipla-announces-exclusive-partnership-with-qilu-pharmaceutical-for-the-licensing-6fcbb6a2cc334bea 2026-09-03T16:23:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-company-in-senegal-produces-first-african-made-clinical-treatment-bcb0ebbefcd25fc6 2026-09-03T16:20:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-eu-pharmaceutical-legislation-why-regulatory-reform-matters-for-ip-teams-c7f706010a11939d 2026-09-03T16:20:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-does-zurzuvae-compare-with-other-antidepressants-for-postpartum-depression-dc1062faa2320f67 2026-09-03T16:12:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-issues-year-long-sop-for-mahaprasad-langar-ahead-of-festivals-to-ensure-food-4a6536f6317c447b 2026-09-03T16:08:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-stocks-to-follow-now-september-3rd-385c65dc54bd1080 2026-09-03T16:05:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-seeks-public-input-to-advance-development-of-botanical-drug-products-31dddb311ddb532f 2026-09-03T15:41:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-s-apazunersen-fails-phase-3-angelman-syndrome-trial-889389931e9b0127 2026-09-03T15:32:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/biolinerx-ltd-nasdaq-blrx-share-price-blrx-stock-news-blrx-share-price-updates-7f60262f5eff496b 2026-09-03T15:23:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-orders-recall-of-arcan-bitters-over-undeclared-drug-substance-94c8f38c713d3c90 2026-09-03T15:18:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/kali-therapeutics-receives-u-s-fda-clearance-for-kt501-investigational-new-drug-aae488d1a2c414ed 2026-09-03T15:16:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/twinstrand-s-245m-win-signals-growing-value-of-biotech-patent-monetisation-14eeaebdc54d0c17 2026-09-03T15:11:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/nottingham-professor-awarded-international-pharmaceutical-federation-fellowship-3fc85d6768441daa 2026-09-03T15:02:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-is-summit-therapeutics-stock-soaring-today-summit-therapeutics-nasdaq-smmt-9318bb4b935a74eb 2026-09-03T14:57:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-announces-positive-topline-results-from-the-phase-3-cervino-trial-showing-e891ac294dba1fe7 2026-09-03T14:55:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/maha-fda-unveils-permanent-food-safety-calendar-for-festivals-778a0301f9805c0f 2026-09-03T14:54:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/decision-marketing-authorisations-granted-in-2026-5c68a1e21768a156 2026-09-03T14:49:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/decision-parallel-import-licences-granted-in-2026-b764e0478035f182 2026-09-03T14:49:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/field-safety-notices-24-to-28-august-2026-e820c4ea97bf741e 2026-09-03T14:45:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/seattle-scientists-launch-95-million-ai-biology-effort-02697c531b6efbaa 2026-09-03T14:41:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/avacopan-safety-concerns-grow-amid-liver-injury-signals-reports-us-registry-anal-e2c80021015aa223 2026-09-03T14:30:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-and-marburg-haemorrhagic-fevers-outbreaks-and-case-locations-16b29cdb0bb31831 2026-09-03T14:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/outbreaks-under-monitoring-in-2026-eb6ae222898106b1 2026-09-03T14:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/controversial-drug-suspended-due-to-trial-irregularities-71679c947d63120b 2026-09-03T14:24:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-eid-to-diwali-maharashtra-fda-led-by-tukaram-munde-announces-year-round-rul-2c5811935cac6a38 2026-09-03T14:19:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/sweets-cooking-oil-and-community-feasts-to-face-stricter-checks-as-maharashtra-f-cf6cdf0f198ea302 2026-09-03T14:18:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotechnology-firm-to-double-local-workforce-after-leasing-larger-space-4ee1a174c0f80686 2026-09-03T14:18:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/esc-2026-oral-and-injectable-glp-1-comparisons-under-the-spotlight-5f57685e1a0a5d60 2026-09-03T14:05:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-shares-drop-following-failed-phase-iii-clinical-trial-b3e5d2419e353d3e 2026-09-03T13:52:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/eledon-files-islet-cell-transplant-application-plans-phase-3-kidney-trial-9801cbd3516e453e 2026-09-03T13:47:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-nasdaq-rare-hits-new-12-month-low-after-analyst-downgr-4f904266dcbe655d 2026-09-03T13:42:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/keep-your-vaccines-healthy-poster-and-magnet-645e3db5492ab884 2026-09-03T13:41:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-nasdaq-rare-given-new-37-00-price-target-at-canaccord-66c0004b8e1883b9 2026-09-03T13:34:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/hda-proposes-two-year-timeline-for-national-pharmaceutical-distributor-licensure-efa7c2adbb08a13a 2026-09-03T13:27:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/mdd-class-iib-hi-lo-shiley-ec3b7ff501651e60 2026-09-03T13:27:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-tests-over-30-000-food-samples-more-than-15-000-found-below-stan-5551f8b8d9d45244 2026-09-03T13:26:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-bispecific-shows-promise-in-ph-3-multiple-myeloma-trial-d184def1095d8173 2026-09-03T13:20:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/rare-stock-craters-as-aspire-trial-failure-triggers-reset-32a5989619a1475c 2026-09-03T13:18:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-s-experimental-treatment-cut-the-risk-of-disease-getting-worse-or-death-6-a5494b8f45fd1257 2026-09-03T13:16:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-announces-positive-topline-results-from-the-phase-3-cervino-trial-showing-7712a940ff7ff510 2026-09-03T13:15:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/william-blair-downgrades-ultragenyx-pharmaceutical-nasdaq-rare-to-market-perform-2c38e617623ac224 2026-09-03T13:11:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/monte-rosa-therapeutics-high-stakes-drug-pipeline-balanced-by-a-fortress-balance-5b424379b046d58f 2026-09-03T13:06:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/kala-shankle-on-states-timing-and-national-licensure-readiness-a29570559c5d9e91 2026-09-03T13:04:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/safe-food-a-shared-responsibility-not-just-fda-s-job-says-tukaram-mundhe-f656bde45e831364 2026-09-03T13:01:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-2026-to-2027-46b78a2386536090 2026-09-03T13:00:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/syndromic-surveillance-weekly-summaries-for-2026-45747e3878253def 2026-09-03T13:00:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/remote-health-advice-weekly-bulletins-for-2026-0b8fbceac342c05c 2026-09-03T13:00:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-ambulance-syndromic-surveillance-weekly-bulletins-2026-6dee157afd1fba75 2026-09-03T13:00:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/gp-out-of-hours-syndromic-surveillance-weekly-bulletins-for-2026-f212a5a75078c06e 2026-09-03T13:00:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/gp-in-hours-weekly-bulletins-for-2026-dfebf391f225843d 2026-09-03T13:00:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/emergency-department-weekly-bulletins-for-2026-08abcdde2881ef86 2026-09-03T13:00:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/suven-life-sciences-completes-phase-3-enrollment-for-masupirdine-in-alzheimer-s-29fbb841320aeeb3 2026-09-03T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/mosquito-watch-submit-a-mosquito-bd568f4e70a718ed 2026-09-03T12:50:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-inc-rare-stock-price-live-quotes-charts-nasdaq-3540750ffc4c2259 2026-09-03T12:49:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-crackdown-34-584-food-samples-taken-up-for-testing-between-june-b8d57877366cbdbf 2026-09-03T12:48:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-completes-acquisition-of-apogee-therapeutics-3bd03dc0be3cfdc9 2026-09-03T12:34:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/new-data-confirms-innovative-pharmaceutical-industry-is-a-major-economic-engine-aba4b07359d611b4 2026-09-03T12:28:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-alerts-and-statements-65b7066201a76f64 2026-09-03T12:26:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-steps-up-testing-over-37-600-food-drug-samples-collected-in-thre-2f7d0633fe9db2cb 2026-09-03T12:23:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-healthcare-conference-webcast-is-set-for-sept-10-in-new-york-1e8f98d1fcb617e7 2026-09-03T12:21:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/jyong-biotech-announces-participation-in-stockfan-virtual-investor-non-deal-road-9319d9b6ab931362 2026-09-03T12:14:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/krystal-biotech-to-participate-in-2026-cantor-global-healthcare-conference-6b9c103be781eff3 2026-09-03T12:12:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-nasdaq-rare-lowered-to-neutral-rating-by-jpmorgan-chas-d6dae5210c2caa66 2026-09-03T12:10:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-nasdaq-rare-rating-lowered-to-neutral-at-robert-w-bair-23e748d6557c1edf 2026-09-03T12:10:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-nasdaq-rare-rating-lowered-to-equal-weight-at-wells-fa-ea8a01bb92c57369 2026-09-03T12:10:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-to-present-at-the-morgan-stanley-24th-annual-global-healthcare-conference-8c59ada7c6ac7eeb 2026-09-03T12:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/krystal-biotech-to-present-at-2026-cantor-global-healthcare-conference-f43166b67934f065 2026-09-03T12:02:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/first-in-the-baltics-northway-biotech-opens-61-million-cell-therapy-and-personal-a87b8ad77b056c33 2026-09-03T12:01:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/suven-life-sciences-completes-424-patient-phase-3-enrollment-for-masupirdine-in-4bcb3472c79eaadb 2026-09-03T12:00:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/some-of-the-top-biotech-funds-just-bought-into-this-under-the-radar-biotech-nasd-e136ce9977b1d5b4 2026-09-03T12:00:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/billionaire-family-offices-back-healthcare-and-biotech-startups-in-august-0f2796c3e663921e 2026-09-03T12:00:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-plant-based-drug-developer-will-join-a-two-language-online-investor-event-sept-b707f8ac9e35c186 2026-09-03T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-his-parents-basement-to-your-medicine-cabinet-absci-ceo-college-of-science-e926866d72dc8521 2026-09-03T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/priothera-appoints-experienced-biotech-executive-dr-nigel-3a4d080a65e420a3 2026-09-03T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/priothera-appoints-experienced-biotech-executive-dr-nigel-clark-as-chief-busines-f6aedf2072e14833 2026-09-03T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-research-site-community-selects-2026-scrs-eagle-award-finalists-2c880bb3d92a1f8c 2026-09-03T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-s-angelman-syndrome-drug-fails-late-stage-trial-6b4049d5314ab1c4 2026-09-03T11:49:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/gsk-pens-1-3b-hutchmed-deal-for-kras-egfr-cancer-asset-e31680feb091bad4 2026-09-03T11:45:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/wcg-releases-checklist-to-speed-protocol-amendment-implementation-at-clinical-tr-892e7f75d733ba22 2026-09-03T11:37:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-atlas-copco-s-compliant-energy-efficient-solutions-keep-pharmaceutical-utili-4f2ebf75ce697e83 2026-09-03T11:26:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/william-blair-downgrades-ultragenyx-pharmaceutical-to-market-perform-from-outper-2b6b1bf8cab32987 2026-09-03T11:21:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/evercore-isi-downgrades-ultragenyx-pharmaceutical-to-in-line-from-outperform-adj-15c7212b50543081 2026-09-03T11:21:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/reading-an-fda-warning-letter-record-volumes-familiar-failures-e3a9b0b861057990 2026-09-03T11:15:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/investingpro-s-fair-value-model-spotted-puma-biotech-s-95-rally-by-investing-com-67caf919ca21f9d2 2026-09-03T11:13:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/fortrea-s-45m-early-phase-deal-sets-a-90-day-test-for-sponsors-with-active-studi-9a490a30bde2984f 2026-09-03T11:12:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-s-apazunersen-fails-phase-3-primary-endpoint-in-angelman-syndrome-4bb02cc4de268cb9 2026-09-03T11:12:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/eledon-pharmaceuticals-announces-islet-cell-transplantation-ind-submission-first-0cad31bc06f5ac7e 2026-09-03T11:11:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-fails-phase-3-angelman-test-plots-significant-expense-reductions-ebb2a3e917bc4b01 2026-09-03T11:10:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/medicines-reclassify-your-product-5d0f310e38e39b3c 2026-09-03T11:09:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/insider-buys-additional-chf75k-in-veraxa-biotech-stock-bf2714a4c3eb9204 2026-09-03T11:00:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/federal-judge-pauses-case-on-mifepristone-access-until-after-midterm-elections-62f779dda08ba54b 2026-09-03T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/12-people-with-type-1-diabetes-no-longer-needed-insulin-after-transplants-three-69cadbf21e12fe93 2026-09-03T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/eledon-pharmaceuticals-announces-islet-cell-transplantation-6051b080334c5705 2026-09-03T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biocytogen-and-qilu-pharmaceutical-sign-agreement-for-vhh-antibody-molecule-025ca1ea06620367 2026-09-03T10:54:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/abivax-has-still-not-been-acquired-what-s-going-on-9bbd3e7e80750342 2026-09-03T10:34:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/akeso-s-ivonescimab-extends-survival-in-pd-l1-lung-cancer-4eb5e75d6b19d633 2026-09-03T10:24:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/hutchmed-china-signs-licensing-deal-with-gsk-for-experimental-solid-tumour-drug-6fdc52cd79303468 2026-09-03T10:13:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-35523ec4937619f8 2026-09-03T10:12:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-27-september-2026-c943810d2c68d2ca 2026-09-03T10:12:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-older-adults-vaccination-coverage-in-england-aug-16bd5e27d65a23b1 2026-09-03T10:12:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-maternal-vaccination-coverage-in-england-may-202-2cc50be828051e6c 2026-09-03T10:12:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/quarterly-epidemiological-commentary-mandatory-mrsa-mssa-and-gram-negative-bacte-476c46b5e267decc 2026-09-03T10:12:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/last-patient-finishes-72-week-mash-study-for-inventiva-iva-4e1c703a10cc5a32 2026-09-03T10:03:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/heron-therapeutics-stock-trades-at-penny-level-as-biotech-focuses-on-pain-and-on-81fc4b904627f4d4 2026-09-03T09:58:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/nhs-injury-costs-recovery-scheme-april-2026-to-march-2027-8ea107a36a0e2402 2026-09-03T09:56:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/russia-attacks-major-pharmaceutical-storage-complex-in-kyiv-oblast-b233495bba57634d 2026-09-03T09:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/invasive-mosquito-species-detected-in-east-london-27cbec11478637b5 2026-09-03T09:47:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/titan-biotech-jumps-5-on-1-4-bonus-issue-dividend-announcements-c9da73fea54f65e9 2026-09-03T09:43:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/flu-vaccines-2026-to-2027-flu-season-b576f8a56dd971ba 2026-09-03T09:42:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/shaping-the-future-of-pharma-gelita-s-next-gen-excipients-at-cphi-6157863079aaa604 2026-09-03T09:30:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/titan-biotech-s-board-approves-issuance-of-bonus-shares-in-ratio-of-1-4-a366675af4736ae7 2026-09-03T09:18:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/ai-sleep-data-could-provide-one-week-early-warning-of-flu-and-covid-19-a8c7f093a9fa926c 2026-09-03T09:08:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/children-s-public-health-nursing-workforce-and-activity-2025-38e994035a279a7b 2026-09-03T09:06:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/daewoong-pharmaceutical-deepens-cooperation-with-indonesia-s-regulator-c1de9f769fac6bdc 2026-09-03T09:02:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/salmonella-outbreak-update-dbba55fa25793323 2026-09-03T09:01:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-angelman-syndrome-drug-fails-phase-iii-test-53135297270ca56f 2026-09-03T08:59:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/federal-judge-pauses-case-on-mifepristone-access-until-after-midterm-elections-b4af6396308c5ad6 2026-09-03T08:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/daewoong-steps-up-cooperation-with-indonesia-3733838a428656a4 2026-09-03T08:51:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/danish-pension-giants-increased-novo-nordisk-stakes-in-h1-6c60e569428329e6 2026-09-03T08:42:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/engagement-guide-for-infection-and-antimicrobial-resistance-amr-174f9e49abc663e7 2026-09-03T08:37:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/la-aemps-informa-de-un-riesgo-de-acceso-no-autorizado-en-el-sistema-albert-e-mot-66acbce3cedfd018 2026-09-03T08:33:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/environmental-monitoring-following-the-grenfell-tower-fire-85d5cc3f2b36adbc 2026-09-03T08:30:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/adult-social-care-provider-statistics-england-quarterly-update-to-august-2026-84fd9c0dae4b4c16 2026-09-03T08:30:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/adult-social-care-provider-statistics-england-background-quality-and-methodology-5a33757363446dec 2026-09-03T08:30:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/adult-social-care-provider-statistics-england-quarterly-update-e646ed937f385b1f 2026-09-03T08:30:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/surveillance-of-respiratory-syncytial-virus-winter-2024-to-2025-c594e08a26c8ca93 2026-09-03T08:30:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/salmonella-statistical-releases-5659a2d745797007 2026-09-03T08:30:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-older-adults-vaccination-coverage-in-england-b306771583db51df 2026-09-03T08:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-maternal-vaccination-coverage-in-england-e72ee03f6bc9d959 2026-09-03T08:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/hiv-london-annual-data-spotlight-6282540f898afb39 2026-09-03T08:30:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/mosquito-control-c8b19194e5a7a25e 2026-09-03T08:18:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-stocks-at-52-week-highs-oabi-13-frnm-exel-fth-lfst-2e50687fe324c1c7 2026-09-03T08:08:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/annji-submits-application-to-u-s-fda-for-phase-3-clinical-trial-of-aj201-5207a59b9553f77e 2026-09-03T07:57:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/la-aemps-informa-del-cese-de-comercializacion-retirada-del-mercado-y-recuperacio-d7c74ef33232d281 2026-09-03T07:56:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/russia-strikes-ukraine-s-largest-pharmaceutical-warehouse-losses-could-reach-bil-3567df19810183c4 2026-09-03T07:52:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ivonescimab-meets-overall-survival-endpoint-against-pembrolizumab-in-phase-iii-t-ce718663a02288e2 2026-09-03T07:42:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/fortrea-s-45m-early-phase-acquisition-will-reshape-your-phase-i-startup-timeline-05179ce26d7d3e20 2026-09-03T07:37:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/bulgarian-pharma-industry-protests-overt-politicisation-of-medicines-policy-700d9b57e0a63a54 2026-09-03T07:36:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/nsabp-b-59-failed-the-real-question-is-why-we-keep-designing-trials-that-can-t-d-48bd1b32fb97c719 2026-09-03T07:32:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-s-angelman-syndrome-drug-fails-pivotal-phase-3-trial-5651d20c84e50171 2026-09-03T07:31:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/rare-looks-41-3-undervalued-on-gf-valuetm-after-phase-3-setback-3472fe9fdebeb9eb 2026-09-03T07:24:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/titan-biotech-board-approves-bonus-share-issuance-b509311b2c6969f4 2026-09-03T07:03:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/tscan-therapeutics-cuts-75-of-workforce-pauses-phase-3-alloha-2-trial-for-tsc-10-0e615d16ac4309a7 2026-09-03T06:47:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/nanochon-enrolls-first-patient-in-chondrograft-knee-cartilage-study-84016f09cb28bd9f 2026-09-03T06:42:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/inventiva-completes-nativ3-phase-3-trial-of-lanifibranor-in-mash-4408a2f67e0410dc 2026-09-03T06:42:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/14-new-weight-loss-drugs-8f97f67645d6c678 2026-09-03T06:29:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-warehouse-reported-on-fire-after-russian-drone-attack-in-ukraine-f91767780426fb59 2026-09-03T06:13:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/indonesian-regulator-visits-daewoong-research-center-af1f35ce26ac2433 2026-09-03T06:12:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/vessl-ai-supplies-sk-biopharmaceuticals-128-nvidia-b200-gpus-to-fuel-r-d-chosunb-83c80d51719dcb02 2026-09-03T05:59:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-drops-on-phase-3-trial-failure-for-angelman-syndrome-drug-rare-nasdaq-e5e6b1558958846f 2026-09-03T05:55:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/korea-united-pharmaceutical-succeeded-in-re-certifying-the-ukrainian-drug-manufa-0e3667859f8cfb47 2026-09-03T05:49:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-to-avoid-common-contamination-control-mistakes-in-new-aseptic-facilities-bb17139a7fb32478 2026-09-03T05:48:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/mint-venture-partners-lists-three-biotech-bets-on-kosdaq-2191b8f255058e37 2026-09-03T05:47:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/gsk-agrees-to-pay-110-million-for-hutchmed-cancer-drug-rights-879a2fc3651283b3 2026-09-03T05:27:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/indonesia-s-bpom-visits-daewoong-pharmaceutical-s-magok-r-d-center-to-expand-reg-4de9e02ba3c4cde6 2026-09-03T05:03:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-orders-immediate-recall-of-arcan-bitters-over-drug-adulteration-88aafee8e0afa456 2026-09-03T04:43:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/2-2026-34ac1ec53a3e4337 2026-09-03T04:42:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/robotics-ai-in-pharmaceutical-manufacturing-9a735dc6c0868c57 2026-09-03T04:35:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/eisai-and-biogen-announce-china-approval-of-leqembi-sc-ai-for-initiation-treatme-93067c7018dba048 2026-09-03T04:10:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-outbreak-table-is-showing-17-active-investigations-37464e61b525f64b 2026-09-03T04:06:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/leqembi-lecanemab-subcutaneous-formulation-as-an-initiation-treatment-for-early-110a7765be93bf34 2026-09-03T04:00:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/america-s-new-drug-dealers-have-moved-from-street-corners-to-the-internet-and-th-77877996a0a16e2a 2026-09-03T04:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/spinal-cord-stimulator-recall-boston-scientific-removes-infinion-cx-lead-65b558bea0c49e11 2026-09-03T04:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/monitoring-system-correction-ge-healthcare-updates-use-instructions-for-portrait-b85b00625bf9b90c 2026-09-03T04:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/early-alert-heart-pump-controller-purge-cassette-issue-from-abiomed-04c7962787145431 2026-09-03T04:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/early-alert-breathing-circuit-issue-from-draeger-d5c9d433b1e38f07 2026-09-03T04:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/israeli-ag-biotech-company-to-set-up-north-american-hq-in-indiana-20bf6997cd4f9e26 2026-09-03T03:52:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/russian-far-east-universities-and-pharma-group-partner-on-marine-based-biotech-7f12b55ceb230d3b 2026-09-03T03:42:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/brandon-capital-s-60m-taypayer-funded-biotech-bets-fcd7d0145adac3bb 2026-09-03T03:42:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/shinsa-english-translation-of-review-report-akuugo-partial-change-approval-04b818dca2e48622 2026-09-03T03:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/shinsa-points-to-consider-for-the-evaluation-of-the-effects-of-food-on-the-pharm-631aad808822c180 2026-09-03T03:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ivonescimab-monotherapy-demonstrates-statistically-significant-overall-survival-f35cba7f06714f8d 2026-09-03T02:01:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/oncosil-pursues-a-reimbursement-pathway-as-it-prepares-for-us-rollout-d8655e4eb1f3d3f0 2026-09-03T01:48:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-biotech-services-enters-cooperation-agreement-a411b5dd359e3024 2026-09-03T01:04:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/onconic-therapeutics-wins-south-korea-approval-to-begin-phase-3-h-pylori-trial-c-df56cd87d06f8bb4 2026-09-03T00:19:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-filed-form-8-k-8ed1dc98747e9b33 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-request-30-day-public-comment-request-4b636f3d14fc39a2 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/determination-that-phenaphen-with-codeine-no-3-acetaminophen-codeine-phosphate-o-f6afc4514dc89e2e 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/emergency-use-authorization-declaration-1407ab0d73e22187 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-institute-of-mental-health-notice-of-meeting-c93b5de36847c168 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-unspecified-product-b1067504549d2a56 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tips-for-managing-fall-allergies-022a21a7aa0fcc73 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/qfr-guided-versus-ivus-guided-with-qfr-confirmation-for-drug-coated-balloon-trea-cdfb448cad6522ee 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/may-2025-therapeutic-delivery-industry-update-6443de1442a3a87f 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/corrigendum-to-brief-mindfulness-intervention-for-adults-with-cannabis-use-disor-6d5023f773e6048a 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmacokinetic-properties-of-the-clinical-drug-candidate-pri-002-with-regard-to-a7b6ed8d34af1b34 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bicistronic-cd19-cd22-car-t-cell-therapy-in-pediatric-b-cell-acute-lymphoblastic-bafa8b2e322dce4b 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-operator-experience-level-on-clinical-outcomes-of-indirect-and-direct-3b518c5ead5f1d8e 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/symptom-control-proportion-using-patient-reported-outcomes-by-palliative-care-te-d09f0503cf931f5f 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-of-pr-interval-with-illness-duration-and-lymphocyte-count-in-asian-a-4b263d4f54a0b591 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hydrogen-peroxide-driven-electrophysiological-remodeling-ros-mediated-voltage-ga-8c90b69f5e776ff1 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/therapy-challenges-and-child-cohorts-where-the-need-to-treat-is-the-only-option-fd0c27352b464ef6 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sleep-apnea-hypopnea-in-children-evidence-that-lize-tongqi-decoction-with-acupun-b180aa9cd97330d0 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmacotherapy-of-heart-failure-impact-of-the-2021-guideline-update-on-guidelin-b4ab87d136ac0e81 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-operator-experience-level-on-clinical-outcomes-of-indirect-and-direct-120dd9ece6ef3538 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bioimpedance-from-body-composition-assessment-to-emerging-technologies-in-clinic-e84f95ada897817b 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/transcranial-direct-current-stimulation-in-anorexia-nervosa-a-randomized-sham-co-a4a46e9df1c41167 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-cumulative-electrical-risk-score-is-associated-with-appropriate-icd-therapy-in-7ef49eeaf320c373 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-significance-of-maternal-anti-d-antibody-titers-in-severe-rhd-alloimmun-65404e4c99ff7550 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/limited-predictability-of-traumatic-intracranial-hemorrhage-from-routine-pre-ct-5d2028888b43b239 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-assessment-of-obesity-beyond-body-mass-index-adiposity-evaluation-body-f6993fbb729841a9 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/co-directional-chromosomal-clustering-of-metabolic-pathway-genes-as-a-layout-pri-67ec43dc5048e366 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fenofibrate-in-ophthalmology-therapeutic-efficacy-and-mechanisms-eb91509f713f76a2 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/validation-of-a-commercial-intraoral-auto-segmentation-algorithm-against-expert-ac559981ac6f5b60 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/acceptability-and-feasibility-of-the-ushirikiano-treatment-model-for-kenyan-adol-6b8593f015316a22 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/staff-mediated-doll-therapy-in-chinese-residential-dementia-care-an-exploratory-df2f7edd9923714c 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/case-report-mature-tertiary-lymphoid-structures-in-a-metastatic-urothelial-carci-5be9ce5a12403608 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-expression-and-clinical-significance-of-sirt5-h2a-and-top2a-in-cervical-canc-22b2131009e25a50 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pediatric-stroke-in-inborn-errors-of-metabolism-clinical-characteristics-neuroim-e9a39a60ac1b20b2 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-efficacy-of-the-galdakao-modified-supine-valdivia-position-vs-the-litho-6f472f987bf194a5 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/case-report-soft-endoscopic-treatment-of-herlyn-werner-wunderlich-syndrome-an-in-e6e15ba7a480d0fd 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/immunogenicity-and-safety-of-a-single-dose-of-adjuvanted-rsvpref3-vaccine-in-adu-314188cb964801b0 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/application-of-the-boppps-model-combined-with-flipped-classroom-in-clinical-prac-aedb6015c93ab006 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-perioperative-outcomes-of-computer-guided-versus-conventional-plan-812dcb7e8cb1be77 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/editorial-therapeutic-targeting-of-cell-death-in-cardiovascular-diseases-from-me-c39a4a66405473be 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-outcomes-of-external-fenestration-tevar-in-stanford-type-b-aortic-disse-dfde2ef53d47dfde 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-clinical-prediction-model-for-post-procedural-hemolysis-after-transcatheter-vs-76ab0e3da393a23d 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cardiac-safety-of-l-annamycin-a-pooled-analysis-of-five-clinical-trials-e0dfccb4be31a915 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/treatment-shortening-and-relapse-control-in-drug-susceptible-pulmonary-tuberculo-d0ffd3b5d5ec68a1 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-and-initial-validation-of-an-instrument-measuring-the-perceived-impo-73eca2313dc278e8 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/real-world-minimal-residual-disease-assessment-in-multiple-myeloma-using-a-stand-2a56eb19997102c5 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrated-clinical-anthropometric-cardiometabolic-and-autonomic-determinants-of-d2755d97ec2d9e04 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/personalized-mrna-neoantigen-vaccines-reach-phase-iii-a-critical-commentary-on-t-4d5cc16668f643ad 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrating-molecular-engineering-and-artificial-intelligence-to-overcome-clinic-e47531eaa091416c 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-feasibility-and-procedural-efficiency-of-a-trephine-based-digital-surgi-054db21b123370f3 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/crestal-bone-loss-in-mandibular-telescopic-implant-retained-overdenture-with-mil-41243a9cfa7408b3 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-correlates-of-follow-up-discontinuation-in-adult-psychiatric-outpatient-e8acf6cef829a517 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evolution-of-the-legal-regulation-of-nicotine-containing-products-in-the-russian-b145c6833a20b0c7 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/criminal-law-characteristics-of-propaganda-of-narcotic-drugs-in-information-and-5eb19c99b74bc4ca 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biomarkers-in-retinopathy-of-prematurity-expanding-horizons-toward-non-invasive-e061daf423d69334 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/toward-harmonized-reporting-of-alzheimer-s-disease-biomarkers-in-clinical-practi-1c9864ef9fc636f9 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluating-feasibility-of-ferritin-assay-harmonisation-with-commutable-proof-of-c68a5c131cf180ce 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/assessment-of-testicular-function-in-boys-with-hematological-malignancies-a-pros-85d1a1e7b0937e6f 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-pharmacokinetic-and-pharmacodynamic-study-of-enteric-coated-sustaine-88476cfd2c712d82 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/management-of-job-stress-among-higher-education-academics-a-randomised-controlle-f609565c3431ce3b 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/correction-maze-out-a-study-protocol-for-a-randomised-controlled-trial-using-a-m-b8d1d9481acd5f89 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/inflammatory-macrophages-promote-metastatic-potential-in-triple-negative-breast-5b1cfa72c034d99b 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-association-of-involvement-in-clinical-activities-and-job-satisfaction-among-0c2113447c240a0c 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/3-dimensional-human-ipsc-derived-cardiac-organoids-for-antifibrotic-drug-screeni-327080c375c27d07 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/supplementary-figure-s3-from-a-patient-derived-xenograft-repository-capturing-cl-1bb875fc355d151b 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/supplementary-figure-s5-from-a-patient-derived-xenograft-repository-capturing-cl-dbca5a634b2d4be6 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/supplementary-figure-s6-from-a-patient-derived-xenograft-repository-capturing-cl-6b0c8c46f89bbe20 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/supplementary-figure-2-from-safety-and-clinical-outcomes-of-a-first-in-human-tri-7e5419b380288ee6 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/supplementary-table-2-from-safety-and-clinical-outcomes-of-a-first-in-human-tria-69bb7cc4cdc06ac2 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/supplementary-table-s4-from-tumor-infiltrating-clonal-hematopoiesis-is-associate-cf4a365d08ef7264 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/supplementary-table-s5-from-tumor-infiltrating-clonal-hematopoiesis-is-associate-2cfa8f429c2213bc 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-between-global-longitudinal-strain-and-pacing-induced-cardiomyopathy-cfa4490a36473a3c 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/macrophage-foxo1-inhibition-protects-against-hyperglycaemia-associated-kidney-in-529780b59f9a549c 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-impact-of-endoscopic-ultrasound-guided-fine-needle-biopsy-in-radiologic-4cb4a79654db3e5d 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/uncommon-benign-tumour-of-the-scalp-9c6984be86a129db 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/phase-3-trial-of-oral-infigratinib-in-children-with-achondroplasia-beadc928530874a3 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-demographic-characterization-of-tinnitus-and-factors-associated-wit-69e6ccebc5aa439e 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-repeated-exposure-to-an-identical-multi-user-virtual-reality-anaphylax-ef38074b9f59984b 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/randomized-trial-comparing-effects-of-high-speed-cued-yoga-and-hatha-yoga-on-cog-cc2e015ee5653ae0 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/limited-benchmarks-constrain-the-conclusions-of-a-general-purpose-versus-clinica-e58ff25e96475cc6 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/reply-to-limited-benchmarks-constrain-the-conclusions-of-a-general-purpose-versu-a56657bf155b0abc 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-sacubitril-valsartan-on-serum-uric-acid-and-blood-pressure-in-patients-6378ddefd7cd8a1e 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-evaluation-of-calcium-chloride-and-polyethylene-glycol-400-on-drug-l-bbf22ecfb9b45a09 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-conventional-molecular-graphs-multigraph-based-topological-descriptors-fo-48432f2f93b11c08 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/transnasal-administration-of-surfactant-aerosol-to-the-lungs-of-infants-using-di-15e0d98bf43c71fa 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/semaglutide-bioavailability-limitations-formulation-innovation-and-future-opport-86ea1f2e2c2800f6 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/an-orthogonal-framework-for-higher-order-structural-and-in-vitro-functional-comp-0010ab880b5503ac 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sodium-glucose-cotransporter-2-inhibitors-and-gastrointestinal-neoplasm-risk-in-6adf5f6a47736c62 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/predicting-psychiatric-drug-initiation-after-craniectomy-a-retrospective-cohort-26f3d11ac448941a 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/oral-health-and-functioning-in-older-adults-in-switzerland-from-1970-to-2025-a-s-16c8b53579418da3 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/vascular-and-autonomic-recovery-after-resistance-training-with-and-without-post-8066e974c23d4808 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/volumetric-and-functional-connectivity-alterations-of-the-thalamus-and-thalamic-eb2eea0aa27ca4a0 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07803549-the-effect-of-self-management-interventions-among-patients-with-brea-3ca15db906d2ebc5 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07803471-yiqi-fumai-lyophilized-injection-for-chronic-heart-failure-caused-by-a2f07156d8dd8c5f 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07803120-effects-of-external-upper-limb-loading-on-gait-and-trunk-muscle-acti-4feef7e864160149 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07802834-adjuvant-ctdna-adapted-treatment-with-zipalertinib-in-early-stage-at-c2d7d080dba11bf8 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07802132-a-prospective-observational-single-arm-multicenter-real-world-study-fd91cda2be97b0e7 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07801417-clinical-biochemical-evaluation-of-antioxidant-vs-chlorhexidine-as-a-c93a6c9e605280c4 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07801339-clinical-evaluation-of-immediate-dental-implants-in-very-elderly-pat-6b66b3ce91e03bca 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07786701-treatment-of-camptodactyly-with-radial-longitudinal-flap-versus-full-ab0801914f16114b 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07719725-effects-of-visual-feedback-induced-therapy-and-active-release-techni-3f43b35d6a434bf8 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07684235-extension-trial-to-evaluate-the-long-term-efficacy-safety-and-tolera-f33b5bffb01a2fc3 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07678931-study-on-the-treatment-of-adolescent-patients-with-seasonal-allergic-fc4b86a86c347df7 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07661108-a-clinical-study-of-mk-8527-in-healthy-participants-mk-8527-021-18f74983ac589a48 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07630831-patient-navigation-for-improving-transition-success-among-multiply-d-f711752150395a13 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07620561-efficacy-and-speed-of-response-of-lebrikizumab-in-high-burden-prurig-54feb83b5d470419 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07606144-pecha-kucha-based-eras-education-in-cardiovascular-surgery-effects-o-e856b226ac56abb1 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07600749-clinical-study-of-mk-4884-in-participants-with-advanced-or-metastati-2d41f3a6b028aa9b 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07594730-brief-intervention-addressing-stigma-among-parents-of-children-with-bbf85563aa96deac 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07585968-safety-and-effectiveness-of-the-sphere-9tm-catheter-and-afferatm-abl-6e22d8fa3f907fc6 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07545811-study-of-janx014-in-subjects-with-metastatic-castration-resistant-pr-6aa1e42bc6852e37 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07545265-skb565-for-injection-in-advanced-solid-tumors-0cc1c6106d9c46c0 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07538518-pet-imaging-study-using-evuzamitide-to-detect-cardiac-amyloidosis-in-0dea7794766b509d 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07519772-a-clinical-study-of-mk-1045-in-people-with-non-hodgkin-lymphoma-mk-1-a50ac56f09684b1d 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07489495-a-clinical-study-of-belzutifan-mk-6482-and-zanzalintinib-in-people-w-a3e0d6fe17ba3f25 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07484620-physical-activity-and-fitness-in-pediatric-inflammatory-bowel-diseas-bc58426f4ec17f87 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07414992-a-study-of-radiation-therapy-and-cemiplimab-with-or-without-fianlima-ff8eb97481943626 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07326566-study-of-silevertinib-with-temozolomide-for-the-treatment-of-newly-d-c79f0cf666642e01 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07280468-endotype-directed-treatment-for-osa-in-down-syndrome-8211218c37c40f9f 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07156227-testing-the-addition-of-an-anti-cancer-drug-camonsertib-to-radiation-9e32cb0460922608 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07047079-patient-navigation-based-preoperative-rehabilitation-exercise-progra-fac1c36c1193f8d5 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07026331-effect-of-balloon-angioplasty-vs-stenting-following-residual-stenosi-c505d4bff28bb9fb 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06989359-phase-2-study-of-adx-038-in-complement-mediated-kidney-disease-e19805be6982b1bf 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06975176-combating-hiv-stigma-in-healthcare-settings-a-standardized-patient-a-62493b8d11a4810f 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06959979-novel-molecular-targets-and-innovative-therapeutic-perspective-in-me-74e9efac56b00105 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06905834-evaluation-of-allogenic-mesenchymal-stem-cell-msc-injection-therapy-f1544c84fa352983 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06868914-phase-i-trial-of-high-density-theta-burst-stimulation-hdtbs-50974328c917c8e9 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06851767-base-edited-hematopoietic-stem-progenitor-cell-x-linked-severe-combi-7e80bdcae407fc6b 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06790693-a-study-evaluating-the-efficacy-and-safety-of-inavolisib-plus-cdk4-6-6f1e9caf08c3d834 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06750484-trial-of-trastuzumab-deruxtecan-in-previously-treated-her2-03b4259de70d475c 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06727565-study-of-novel-treatment-combination-therapies-in-participants-with-a2f6e6c632fa60cd 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06703489-safety-and-performance-assessment-of-the-sphere-9tm-catheter-and-aff-1cc56312f9c981ee 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06514937-efficacy-of-the-e-motional-training-program-for-improving-social-cog-9535cd8a7afffeb3 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06470750-feasibility-of-patient-centered-home-care-pchc-to-reduce-disparities-69e48f5038e920ae 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06445972-substudy-06d-combination-therapies-in-second-line-2l-gastroesophagea-6f0d2f1c8dfd9ede 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06337318-comparing-rituximab-and-mosunetuzumab-drug-treatments-for-people-wit-f9c0f74dff068b0e 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06245889-pet-dynamics-to-response-adapted-neoadjuvant-therapy-in-tnbc-24e00a5a88014a96 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06227611-evaluation-of-different-perimetric-grids-to-detect-central-visual-fi-392c69ea0a8d73af 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06203600-adding-nivolumab-to-usual-treatment-for-people-with-advanced-stomach-520cb5d107702f36 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06064097-a-study-using-nivolumab-in-combination-with-chemotherapy-drugs-to-tr-f27a51555e8948ac 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05691478-a-study-to-test-the-addition-of-the-drug-cabozantinib-to-chemotherap-faed8be82b31b368 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05491980-florida-cerebrovascular-disease-biorepository-and-genomics-center-3202d9d4647f154a 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05282732-retrospective-analysis-of-performance-and-treatment-data-collected-f-f7ad16b33e06ba05 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05009459-evisualisation-of-physical-activity-and-pain-evis-for-patients-with-92f624b0141e3d20 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04873362-a-study-evaluating-the-efficacy-and-safety-of-adjuvant-atezolizumab-b9c89b5d7939fa46 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04677049-study-of-niacin-in-glioblastoma-6e89a79f7981eabb 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04657991-a-clinical-trial-of-three-study-medicines-encorafenib-binimetinib-an-29a145dafe104c25 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04628767-testing-the-addition-of-medi4736-durvalumab-to-chemotherapy-before-s-d432900cd209dde8 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01343342-genes-omega-3-fatty-acids-and-cardiovascular-disease-risk-factors-cbf4d01a13c14f7d 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01011712-the-natural-history-of-severe-viral-infections-and-characterization-273f119f11e3c127 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct00040352-clinical-laboratory-and-epidemiologic-characterization-of-individual-0698a34f21953ae4 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sputum-based-test-may-identify-drug-targets-in-asthma-and-copd-patient-care-onli-d603f129595215f0 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/otsuka-holdings-publishes-integrated-report-2026-a4b1fbb930580ca0 2026-09-03T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/experimental-ms-drug-bests-approved-therapy-in-cutting-relapses-in-2-trials-4a2babdd479fc2bf 2026-09-02T23:21:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/mark-your-calendar-the-wbur-breakfast-club-brings-together-founders-and-ceos-res-ef50ee167c3fc9e1 2026-09-02T23:13:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/adaptive-biotechnologies-nasdaq-adpt-director-reports-stock-gift-still-holds-66-caea8e5333f28d79 2026-09-02T23:12:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-to-properly-leverage-fda-flexibility-canva-573eb6ab91a45304 2026-09-02T23:01:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/shaanxi-micot-pharmaceutical-technology-co-ltd-bec6d3a26c697399 2026-09-02T22:40:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-s-rinvoq-restores-80-hair-growth-in-severe-alopecia-areata-phase-3-trial-ab5af11c40880b9f 2026-09-02T22:26:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/revolution-medicines-announces-nejm-publication-of-phase-1-2-rasonque-data-suppo-66b7850ad6e76c80 2026-09-02T22:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/an-experimental-lung-cancer-drug-held-disease-in-check-for-89-of-patients-in-one-525bfa9850259641 2026-09-02T21:50:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-care-up-on-biotech-momentum-health-care-roundup-17dff033cce682bd 2026-09-02T21:42:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-drug-rises-to-the-gluten-challenge-stopping-intestinal-damage-in-celiac-dis-39a3798b54f80a27 2026-09-02T21:41:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-trial-finds-less-intensive-drug-combination-is-more-effective-than-stan-6e4bc03a4ce4e1e3 2026-09-02T21:20:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/hygen-promotes-omid-ghobadi-to-coo-as-pharmaceutical-distributor-expands-0075dc505745381e 2026-09-02T21:06:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-drug-to-treat-angelman-syndrome-a-rare-disease-fails-late-stage-trial-08b478046478cf85 2026-09-02T20:51:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-971303b30f546b58 2026-09-02T20:43:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-firm-buys-former-merrimack-anheuser-busch-brewery-for-47-million-d712ff1c239730fc 2026-09-02T20:40:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/plant-based-eczema-drug-firm-devonian-dvhgf-lines-up-u-s-ipo-but-only-if-one-con-eb9126b5333852eb 2026-09-02T20:35:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/navigating-the-regulatory-labyrinth-how-biotech-leaders-are-rethinking-strategy-872ead8b5d215f44 2026-09-02T20:23:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/consun-pharmaceutical-group-sehk-1681-lifts-earnings-and-dividend-on-a-valuation-56bea6a410da2ca9 2026-09-02T20:19:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-orders-recall-of-arcan-bitters-over-undeclared-drug-substance-f758533ae9392abb 2026-09-02T20:14:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/senators-demand-federal-probe-linking-foreign-drug-makers-to-u-s-recalls-a3a5e1078c7ea4cb 2026-09-02T20:11:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/inventiva-e21fa8c6e9fdd810 2026-09-02T20:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/inventiva-announces-last-patient-visit-in-nativ3-phase-3-clinical-trial-of-lanif-56ef0aa40f3df5b5 2026-09-02T20:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/uc1-stock-price-and-chart-ham-uc1-0bea85fdbbc1cbeb 2026-09-02T19:45:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/is-west-pharmaceutical-services-wst-undervalued-or-already-fully-valued-540404a08e815f7b 2026-09-02T19:41:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/st-louis-biotech-raises-10m-and-names-new-ceo-as-cancer-treatment-advances-862f21ae68cce7f9 2026-09-02T19:41:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-orders-recall-of-arcan-bitters-over-undeclared-sildenafil-content-c038136e31f6e5f8 2026-09-02T19:24:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-adds-its-strongest-warning-to-a-common-iv-iron-drug-over-dangerously-low-pho-c0aea84dea9eedf6 2026-09-02T19:20:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-bristol-myers-pause-autoimmune-car-t-trials-over-safety-concerns-report-b6b580d2f9bcfeb8 2026-09-02T19:08:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/solving-batch-variability-issues-6e881b9d0e00e02a 2026-09-02T19:08:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fifarma-w-a-i-t-indicator-2026-do-tempo-de-espera-a-oportunidade-de-avancar-152ce3927b5a7dce 2026-09-02T19:06:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/fortrea-boosts-early-phase-cro-platform-with-45m-acquisition-of-worldwide-divisi-3eb5e65911852c58 2026-09-02T19:06:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/3d-retina-model-reveals-cause-of-vision-loss-in-batten-disease-0f84fd8767187d93 2026-09-02T18:50:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/mccloud-remedy-project-recovery-plan-review-update-e3e3ac54e8fa5ec4 2026-09-02T18:44:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/fifarma-w-a-i-t-indicator-2026-from-waiting-time-to-an-opportunity-to-move-forwa-b4b85f1600f314ee 2026-09-02T18:25:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/withdrawn-cancer-accelerated-approvals-9d91fd407d4e65c0 2026-09-02T17:55:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/american-shoppers-are-so-rattled-by-surging-fda-recalls-that-67-now-avoid-a-whol-3c9c865918c153c5 2026-09-02T17:41:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-expansion-at-levit-green-f9fef5498336c65b 2026-09-02T17:40:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/tscan-therapeutics-sheds-majority-of-staff-pauses-phase-3-trial-amid-funding-sho-37cc678d9a4fa9e5 2026-09-02T17:22:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/healthcare-etf-comparison-fidelity-s-fhlc-vs-invesco-s-biotech-focused-ibbq-7d011210e82c16e0 2026-09-02T17:12:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/mumbai-fda-suspends-eat-club-rani-creators-licences-over-food-safety-and-hygiene-a7895979429b94c4 2026-09-02T17:08:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-suspends-licences-of-2-more-mumbai-food-establishments-over-safe-0fb98eac3fc7afa9 2026-09-02T16:52:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/ukhsa-spend-over-25-000-2026-a8b4b8d9bbff80c2 2026-09-02T16:45:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/ukhsa-spend-over-500-2026-45a3f0a33e5a8499 2026-09-02T16:44:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/relmada-s-ndv-01-bladder-cancer-trial-moves-into-phase-3-what-investors-should-w-6ae6a2ee7fa3d97e 2026-09-02T16:35:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/fortrea-to-acquire-worldwide-clinical-trials-early-phase-services-division-in-45-10377a4c42ad7165 2026-09-02T16:25:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/alnylam-pharmaceuticals-inc-stock-alny-moved-up-by-7-90-on-sep-2-facts-behind-th-4546a421d9c36465 2026-09-02T16:15:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-novartis-s-3-2-billion-enzyme-licensing-deal-means-for-formulation-04244c3b0098bf90 2026-09-02T16:07:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/if-there-s-a-will-there-s-a-way-says-fssai-chief-backing-tukaram-mundhe-s-crackd-7266a78d7b18663b 2026-09-02T16:00:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/asian-data-face-global-test-in-biotech-deals-5fcf53e3b2b9ef51 2026-09-02T16:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-issues-red-alert-for-us-heart-pump-system-31590cc1e9ac1c6a 2026-09-02T16:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/can-fite-biopharma-evaluates-earlier-interim-analysis-for-key-liver-cancer-study-11862df3d3b21800 2026-09-02T15:48:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-is-vertex-pharmaceuticals-stock-performance-compared-to-other-biotech-stocks-648698b03644f66c 2026-09-02T15:44:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/when-payers-know-the-price-of-everything-25e1afbc7a228dd2 2026-09-02T15:38:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/krystal-biotech-krys-up-12-since-last-earnings-report-can-it-continue-7f45c9881d5ac2fc 2026-09-02T15:30:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/hsv-1-keratitis-clinical-trial-pipeline-analysis-3-key-61209467016d98c1 2026-09-02T15:26:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/india-busts-firm-faking-expiry-dates-nutrition-labels-on-pepsico-nestle-food-exp-4d92a4d8328572a0 2026-09-02T15:16:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/workwell-1415ead5314a3eea 2026-09-02T15:15:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/auchincloss-us-biotech-s-biggest-threat-isn-t-beijing-it-s-washington-5142e4ec999f4781 2026-09-02T15:14:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-the-independent-pharmacy-cooperative-acquisition-of-usave-pharmacy-group-si-f3321d130021642f 2026-09-02T15:03:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/lilly-s-merida-deal-shows-the-glp-1-king-is-already-thinking-beyond-obesity-63fbcf2c512b2db6 2026-09-02T15:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fifarma-w-a-i-t-indicator-2026-del-tiempo-de-espera-a-la-oportunidad-de-avanzar-d1bab7a311ee97b3 2026-09-02T14:54:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-steps-up-mumbai-inspections-goregaon-kurla-eateries-and-chembur-d72689334c5b0cb4 2026-09-02T14:54:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-autoimmune-antibody-notches-ph-2-win-in-celiac-disease-0e151d573c0d6b4d 2026-09-02T14:52:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-s-immune-disorder-drug-meets-main-goal-in-mid-stage-trial-6245ea409f91eecb 2026-09-02T14:49:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/purple-biotech-jumps-after-new-u-s-patent-allowance-for-captn-3-platform-b8cdddba32e0fa76 2026-09-02T14:47:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tscan-axes-75-of-staff-to-make-room-for-solid-tumor-programs-cabef5148cc9e92d 2026-09-02T14:46:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-claims-success-in-celiac-study-biomarin-ascendis-settle-patent-dispute-014de9a6822360af 2026-09-02T14:20:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/state-challenge-to-policy-permitting-mifepristone-by-mail-paused-until-after-mid-068256b2d2c75f51 2026-09-02T14:17:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-landmark-pancreatic-cancer-drug-00061c57e210ea02 2026-09-02T14:15:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medienmitteilung-gesundheitskommissionen-verlangen-kurskorrektur-bei-der-kvv-rev-20e589365a6e4ca6 2026-09-02T14:13:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-next-generation-of-pharmaceutical-logistics-personalization-cold-chain-expan-8f5c34cab250a72a 2026-09-02T14:11:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/roundup-alteogen-enters-option-license-agreement-with-novartis-newbiologix-synas-f543c5682ab79a48 2026-09-02T13:53:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmacist-training-sites-to-receive-backdated-funding-uplift-ff2c8536276d59f7 2026-09-02T13:47:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/arpa-h-funds-biotechs-working-on-custom-rna-therapies-baa9ec294e130b13 2026-09-02T13:41:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/are-investors-undervaluing-takeda-pharmaceutical-co-tak-right-now-0f84fdff37ff659d 2026-09-02T13:40:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-is-purple-biotech-stock-gaining-wednesday-96fbd407dfa80821 2026-09-02T13:24:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/pesticide-found-in-supplement-brain-eating-amoeba-kills-teen-b12-and-birth-defec-a152bfa020a84766 2026-09-02T13:23:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/hansa-ceo-aguiar-lucander-u-s-listing-is-not-optional-for-european-biotech-79b4c33dd2848b1f 2026-09-02T13:14:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/can-fite-announces-exercise-of-warrants-for-approximately-4-0-million-in-gross-p-8b4b55ad8fa8957a 2026-09-02T13:12:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/relevate-health-and-flora-health-launch-formulary-capability-for-pharmaceutical-6cf235ab28fdddc1 2026-09-02T13:08:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-biotech-bi-weekly-designing-preclinical-oncology-programs-mass-spectrometers-442cc7e29f30c452 2026-09-02T13:08:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/can-fite-biopharma-canf-halves-warrant-price-in-cash-for-warrants-deal-f98cf174b9ca02c3 2026-09-02T13:06:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/federal-judge-pauses-case-on-abortion-pill-access-until-after-midterm-elections-bf0e5c866dc4f1b2 2026-09-02T13:04:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/biocytogen-enters-into-non-exclusive-licensing-agreement-with-qilu-pharmaceutica-564bc72a0fa0af82 2026-09-02T13:04:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/can-fite-announces-exercise-of-warrants-for-approximately-4-0-million-in-gross-p-20195683e046d74a 2026-09-02T13:02:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biomarin-to-participate-in-upcoming-investor-conferences-f5091941aaf6ad32 2026-09-02T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/purple-biotech-ppbt-secures-key-patent-allowance-for-tri-specific-antibody-platf-22490c6129990c1f 2026-09-02T12:59:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-pandemic-prevention-to-pharmaceutical-resilience-why-health-security-should-0cee4213be3006a0 2026-09-02T12:55:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/veru-to-participate-in-fireside-chat-at-the-2026-cantor-global-healthcare-confer-d037618e57230bda 2026-09-02T12:51:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/reg-hikma-pharmaceutical-holding-s-in-company-75b5f343b5d6613b 2026-09-02T12:45:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/federal-judge-makes-big-call-on-major-abortion-medication-case-amid-fda-review-1ff7a40a4171f2a4 2026-09-02T12:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/immunic-to-host-virtual-relapsing-multiple-sclerosis-r-d-day-on-september-9-2026-2ccde2d993db2306 2026-09-02T12:43:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-fda-has-put-its-strongest-warning-on-a-common-iron-infusion-over-dangerously-8572ac4f94a3549e 2026-09-02T12:40:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/72570d4154f880a0 2026-09-02T12:39:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/purple-biotech-ppbt-slides-as-cash-crunch-shadows-preclinical-progress-703e165828e8272e 2026-09-02T12:33:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/veru-to-participate-in-fireside-chat-at-the-2026-cantor-global-healthcare-confer-240bd0e9610780d6 2026-09-02T12:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/german-biotech-days-2026-biotechnology-as-the-key-to-industrial-competitiveness-d98d35f124055096 2026-09-02T12:28:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/aaps-pharmsci-360-microstructure-intelligence-in-predictive-drug-development-par-923856ea1824b374 2026-09-02T12:25:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-new-pancreatic-cancer-drug-could-buy-patients-more-time-5a5ce07e7e4b7611 2026-09-02T12:25:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/first-human-clinical-trial-to-test-precision-form-of-flash-proton-therapy-b95f64c4a6f05e11 2026-09-02T12:20:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/fortrea-to-acquire-worldwide-clinical-trials-early-phase-business-for-45m-d84e590e7a3054ee 2026-09-02T12:15:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/ondine-biomedical-s-nasal-photodisinfection-reduced-surgical-site-infections-by-145772489337f9f1 2026-09-02T12:15:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/asus-partners-with-qualcomm-to-launch-pharmaceutical-ai-assistant-targeting-10-0-42ed7551651fbd8c 2026-09-02T12:09:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/cphi-pharma-awards-2026-finalists-announced-8b43cf76b1312d8b 2026-09-02T12:08:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/north-highland-names-chris-kido-global-head-of-life-sciences-b56e458db3c41da0 2026-09-02T12:01:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/biocytogen-enters-into-non-exclusive-licensing-agreement-with-qilu-pharmaceutica-5dfb1a21c5e5992c 2026-09-02T12:00:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-protection-report-volume-20-2026-f9e0b8a49f9df3c3 2026-09-02T12:00:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/quantum-pureflow-standard-heat-exchanger-high-flow-bfa4d36b4d9c5162 2026-09-02T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/lifepak-35-monitor-defibrillator-016813b99e354aa9 2026-09-02T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/leo-intracranial-self-expandable-stent-and-delivery-system-56f7825c859b46a4 2026-09-02T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bicoag-hemostasis-probe-cc392534b3fde809 2026-09-02T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/north-highland-names-chris-kido-global-head-of-life-sciences-bcd029711fa74027 2026-09-02T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biocytogen-enters-into-non-exclusive-licensing-agreement-with-qilu-pharmaceutica-ff27299ad4b8aa0d 2026-09-02T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/allergan-aesthetics-unveils-the-layered-beauty-report-advancing-the-global-conve-b179363fb45b7e53 2026-09-02T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/kane-biotech-expands-canadian-commercial-reach-with-ontario-medical-supply-inc-1be2643cd66b5fc6 2026-09-02T11:52:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-inks-3-2b-subcutaneous-drug-delivery-deal-with-alteogen-98edddac224b9882 2026-09-02T11:51:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/ppbt-stock-squeezed-between-biotech-promise-and-cash-crunch-b8b36740f2e56456 2026-09-02T11:48:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/purple-biotech-receives-u-s-patent-allowance-for-tri-specific-antibody-construct-a9d3c7b45527b248 2026-09-02T11:41:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/u-s-patent-backs-purple-biotech-nasdaq-ppbt-cancer-antibody-platform-898e9a4d8db913aa 2026-09-02T11:34:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/no-extra-officers-tougher-enforcement-what-fssai-praised-in-tukaram-mundhe-s-fda-1f62992a237c1097 2026-09-02T11:34:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-rhapsido-cuts-ms-progression-in-phase-3-trial-teeing-up-roche-battle-8668e6a20568a204 2026-09-02T11:30:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/china-is-a-threat-to-biotech-s-massive-bull-run-7cc353eba49c1c00 2026-09-02T11:26:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/new-daily-drug-may-offer-alternative-for-those-who-cannot-use-cpap-machines-08b76e6c14c18147 2026-09-02T11:24:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/explained-why-sun-pharma-is-offering-cheaper-drugs-to-trump-administration-f3aed331089aa227 2026-09-02T11:19:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/can-fite-reports-longer-than-anticipated-overall-survival-in-ongoing-pivotal-pha-6b7292d8b754138f 2026-09-02T11:12:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/can-fite-biopharma-to-evaluate-earlier-interim-analysis-timing-in-phase-iii-namo-fde4b672e9c43070 2026-09-02T11:12:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/newron-announces-completion-of-screening-for-enrollment-in-pivotal-phase-3-enigm-83b81d778ea5abac 2026-09-02T11:07:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/peptide-innovator-says-the-drug-class-is-due-for-a-rethink-88a38b02cdd0b0ab 2026-09-02T11:06:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-marketed-injectable-drug-is-expected-to-bring-lifecore-revenue-in-2028-26cd668cc8f2496b 2026-09-02T11:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-e982dd3db21dd0a0 2026-09-02T11:03:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/people-in-a-liver-cancer-study-may-be-living-longer-than-expected-can-fite-may-a-b15d2f61d422b9bd 2026-09-02T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/newron-announces-completion-of-screening-for-enrollment-in-dcc0883ae104bde1 2026-09-02T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bio-rad-expands-chromatography-columns-with-nuvia-ion-exchange-d483e40ca1f5e799 2026-09-02T10:56:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/trinity-biotech-plc-sec-filing-sep-2-2026-d0550ffa8f07d274 2026-09-02T10:48:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/fy2026-annual-results-short-form-announcement-7b13871a2772b542 2026-09-02T10:48:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/fy2026-annual-results-booklet-7b9b4c3719dbfa91 2026-09-02T10:47:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/fy2026-annual-results-presentation-d7b7765be2e8d371 2026-09-02T10:46:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/merck-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference-f0d6609a9a8ddb7f 2026-09-02T10:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ono-pharmaceutical-joins-forces-with-aitia-for-drug-discovery-in-neurology-baeb8ed93ef5afea 2026-09-02T10:12:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/abortion-pill-case-is-frozen-until-december-while-a-federal-judge-waits-for-the-429b9647de35cde8 2026-09-02T10:10:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/federal-regulators-add-their-strongest-warning-to-a-common-iron-infusion-over-da-40080681b38f4178 2026-09-02T10:00:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/filters-should-be-used-during-the-administration-of-parenteral-nutrition-for-pat-a7fbaa2b1ff57c30 2026-09-02T10:00:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/filters-should-be-used-during-the-administration-of-parenteral-nutrition-for-pat-6f36587d9873112a 2026-09-02T09:59:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-and-bms-paused-car-t-trials-revmed-s-pancreatic-cancer-approval-more-mf-f9169315e2153c74 2026-09-02T09:55:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-remibrutinib-a-high-efficacy-oral-btk-inhibitor-significantly-reduces-r-ac21ec08286fe1df 2026-09-02T09:36:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-btk-inhibitor-clears-phase-iii-hurdle-in-relapsing-ms-0148f1262711c2fc 2026-09-02T09:25:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/regulatory-round-up-2-september-2026-a42e8bef3b31fe3e 2026-09-02T09:25:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/analysis-of-online-pharmacy-advertisements-for-non-fda-approved-treatments-95af123c936c88af 2026-09-02T09:17:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/ono-pharmaceutical-joins-forces-with-aitia-for-drug-discovery-in-neurology-fae2deb9bb6dfae6 2026-09-02T09:12:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/qualcomm-asus-launch-pharmacy-ai-agent-for-drug-safety-5b9521aae5f7bde1 2026-09-02T09:09:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/u-s-fda-warning-prompts-taiwan-red-alert-over-heart-pump-device-cf873f10a3be8794 2026-09-02T09:09:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/argenx-has-delivered-18-consecutive-quarters-of-sales-growth-but-is-the-biotech-45c417e002be6760 2026-09-02T09:07:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/royal-bank-of-canada-reduces-stock-position-in-ultragenyx-pharmaceutical-inc-rar-a400d3fcb76b4f2b 2026-09-02T09:02:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/strong-execution-positions-aspen-for-sustainable-growth-d50b87fa331cf77c 2026-09-02T09:01:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/31-2026-49f1c26b11b043e7 2026-09-02T08:40:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/la-aemps-retira-varios-productos-adelgazantes-por-contener-sibutramina-un-princi-5c5c0626c1f29d3e 2026-09-02T08:37:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-biomarin-s-navepegritide-settlement-and-royalty-deal-with-ascendis-could-sha-0ad2aa7bf4ed938b 2026-09-02T08:31:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/mrsa-mssa-gram-negative-bacteraemia-and-cdi-monthly-data-2025-to-2026-46183ecdfec674cc 2026-09-02T08:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/incyte-shifts-to-multi-franchise-biotech-with-1-47cdbe22b572d525 2026-09-02T08:24:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-breaks-btk-losing-streak-in-multiple-sclerosis-141b965e75a3954e 2026-09-02T08:07:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-is-simcere-pharmaceutical-stock-surging-today-by-investing-com-b55165890756e263 2026-09-02T08:05:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-biggest-biotech-funding-rounds-in-august-2026-2b0a1a542b960efb 2026-09-02T08:02:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-is-simcere-pharmaceutical-stock-surging-today-7b5163c2f795425a 2026-09-02T07:47:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharma-companies-warn-greek-prime-minister-medicine-financing-model-has-reached-618ae4c26f614680 2026-09-02T07:42:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-is-simcere-pharmaceutical-stock-surging-today-3c339d20a1e6216c 2026-09-02T07:36:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medipost-recruits-samsung-biologics-veteran-min-ho-sung-as-president-to-accelera-7ca34cc34241944c 2026-09-02T07:33:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/heparegenix-wins-orphan-drug-status-for-darizmetinib-026a3717f3bd3012 2026-09-02T07:31:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/fssai-chief-roots-for-tukaram-mundhe-says-food-safety-is-not-punishment-posting-9734826a58e13b01 2026-09-02T07:18:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/ono-pharmaceutical-partners-with-aitia-to-hunt-new-brain-disease-drug-targets-us-f0c51bf051de7529 2026-09-02T07:12:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-his-parents-basement-to-your-medicine-cabinet-absci-ceo-endeavors-to-create-f88a2388e429988b 2026-09-02T07:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/can-the-biotech-act-deliver-for-europe-3aaea1aafe6c4620 2026-09-02T06:52:48.000Z weekly 0.7